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Tässä opinnäytetyössä testattiin kemiallisten aseiden analysointiin, seulontaan ja 
tunnistamiseen tarkoitettuja menetelmiä (Recommended Operating Procedure, ROP) 
keskushermostoon vaikuttaville yhdisteille, jotka kuuluvat inkapasitoivien kemiallisten 
aineiden piiriin. Kokeissa käytettäväksi näytematriisiksi valittiin pyyhintänäytteet ja 
tutkittaviksi aineiksi keskushermostoon vaikuttavia yhdisteitä: fentanyyli, naloksoni sekä 
amfetamiini. Näytteenkäsittely perustui pyyhintänäytteen uuttamiseen ensin orgaanisella 
liuottimella ja tämän jälkeen vedellä. Vertailtaviksi orgaanisiksi uuttoliuottimiksi valittiin 
dikloorimetaani sekä asetoni ja kokeita suoritettiin kolmelle eri pyyhintänäytemateriaalille: 
Whatman-suodatinpaperille, vanupuikolle sekä puuvillaliinalle. Asetonilla uutettaessa 
saavutettiin huomattavasti suuremmat saannot valituille analyyteille kuin dikloorimetaanilla. 
Saannot olivat myös suhteellisen korkeita vesifraktioissa, jotka olivat uutettu 
dikloorimetaaniuuton jälkeen. 
 
Valittuja yhdisteitä seulottiin ja tunnistettiin pyyhintänäyteuutteista käyttäen sekä 
nestekromatografia-sähkösumutusionisaatio-tandem-massaspektrometriaa (LC–ESI–
MS/MS) että kaasukromatografia-massaspektrometriaa (GC–MS). GC–MS-seulonnassa ja 
-tunnistuksessa hyödynnettiin AMDIS-tietokoneohjelmaa. LC–MS/MS -seulonta perustui 
tunnettujen yhdisteiden etsimiseen käyttäen full scan- ja MRM-menetelmää. GC–MS- ja 
LC–MS/MS-tekniikoiden sekä ROP-menetelmien todettiin olevan soveltuvia valittujen 
yhdisteiden seulontaan ja tunnistamiseen miljoonasosa-konsentraatiotasolla (ppm, µg/g). 
Analyysitekniikoista LC–MS/MS osoittautui soveltuvammaksi valittujen yhdisteiden 
analysointiin. 
 
Pyyhintänäytekokeiden lisäksi tässä työssä validoitiin menetelmä fentanyylin 
määrittämiseksi virtsasta LC–ESI–MS/MS-tekniikalla. Menetelmän näytteenkäsittely 
perustui analyyttien uuttamiseen virtsasta kiinteäfaasiuutolla isotooppileimatun fentanyyli-
d5:n toimiessa sisäisenä standardina kvantitoinnissa. Validointi suoritettiin pitoisuusalueella 
0,5–50 ng/ml fentanyyliä virtsassa. Validointia varten valmistettiin ja analysoitiin kolme 
rinnakkaista näytettä seitsemällä eri pitoisuustasolla päivittäin kolmen päivän ajan. 
Havaitsemis- ja määritysrajan (LOD ja LOQ) todettiin olevan 0,5 ng/ml fentanyyliä 
virtsassa. Mittausten tarkkuus vaihteli -1,2 ja 14,3 %:n välillä ja täsmällisyys 2,7 ja 6,1 %:n 
välillä. Fentanyylin saannoksi kiinteäfaasiuutosta määritettiin 83,8 % pitoisuustasolla 1 
ng/ml ja 90,1 % pitoisuustasolla 25 ng/ml. 
Avainsanat keskushermostoon vaikuttavat aineet, inkapasitoivat 
taisteluaineet, fentanyyli, amfetamiini, naloksoni, LC–MS/MS, 
GC–MS, validointi, virtsa-analyysi, kiinteäfaasiuutto 
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In this thesis Recommended Operating Procedures (ROPs) were tested for sample 
preparation, analysis, screening and identification of central nervous system (CNS) acting 
chemicals, a class of incapacitating chemical agents (ICAs), in wipe samples. The selected 
candidate chemicals were CNS acting drugs: fentanyl, naloxone and amphetamine. The 
sample preparation was based on extraction of analytes from spiked wipe samples 
successively with organic solvent and aqueous solvent. Two different organic solvents, 
dichloromethane and acetone, and three different wipe materials, cotton swab, Whatman 
filter paper and cotton wipe, were used in the ROP testing experiments. Acetone provided 
high recoveries for the candidate chemicals whereas dichloromethane extracted the 
analytes poorly. Relatively high recoveries were achieved with water extraction performed 
after the extraction with dichloromethane.  
 
Screening and identification of the candidate chemicals in cotton wipe were performed by 
using both liquid chromatography-electrospray ionization-tandem mass spectrometry (LC–
ESI-MS/MS) and gas chromatography-mass spectrometry (GC–MS). AMDIS software was 
utilized in GC–MS screening. The LC–MS/MS screening was targeted screening using full 
scan mode and multiple reaction monitoring (MRM). Both GC–MS and LC–MS/MS 
techniques and the tested ROPs were evaluated to be valid for screening and identification 
of the chemicals in question at parts-per-million (ppm, µg/g) concentration levels. From 
these two analysis techniques, the LC–MS/MS was found to be more appropriate 
technique for analysis of the candidate chemicals. 
 
In addition to the wipe sample study, a quantitative method for determining fentanyl in 
urine by LC–ESI–MS/MS was validated. The assay was based on extraction of fentanyl 
from human urine using solid phase extraction (SPE). Deuterium labeled fentanyl-d5 was 
used as internal standard in quantitation. Validation of the method was studied in the 
concentration range of 0.5–50 ng/ml. The validation experiments were carried out by 
preparing and analyzing three replicate calibration standards at seven different 
concentration levels each day during three days. Limit of detection (LOD) and limit of 
quantitation (LOQ) were determined to be 0.5 ng/ml. The accuracy ranged from -1.2 to 
14.3 % and the intermediate precision from 2.7 to 6.1 %. The extraction recovery of 
fentanyl was determined to be 83.8 and 90.1 % at concentration levels of 1 and 25 ng/ml, 
respectively.  
Keywords central nervous system acting chemical, incapacitating 
chemical agent, recommended operating procedure, wipe 
sample, amphetamine, naloxone, fentanyl, validation, LC–
ESI–MS/MS, GC–MS, urine analysis, solid phase extraction 
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1 Introduction 
This thesis was conducted at Finnish Institute for Verification of the Chemical Weapons 
Convention (VERIFIN) which operates under the Department of Chemistry at the 
University of Helsinki. The institute was established in 1994 to continue the Chemical 
Weapon research project (CW Project) started in 1973. VERIFIN supports the 
verification of the Chemical Weapons Convention (CWC) in the fields of research and 
training. The research in VERIFIN focuses on developing analytical methods for 
screening and identification of chemical warfare agents (CWAs), including their 
degradation products and starting materials. The institute trains and organizes courses 
for chemists from the developing countries. VERIFIN also acts as the National 
Authority of Finland for the CWC. [1] 
This thesis focuses on analytical methods for detecting central nervous system (CNS) 
acting chemicals, a class of incapacitating chemical agents (ICAs). There has been an 
interest in the possibility of using chemicals that can cause incapacitation in humans for 
military, law enforcement or counter-terrorist purposes. These agents include a large 
variety of different chemicals with separate actions and effects. Especially drug-related 
compounds have been investigated for use as incapacitans [2, pp. 23–25]. 
Development of ICAs and their delivery system has been continued for over 50 years 
[3, p. 2].  A number of programs on research and development of ICAs have been 
reported, including programs taking place during the Cold War and contemporary 
programs [3]. The use of CNS acting chemicals against Chechen terrorist at the 
Dubrovka Theatre in Moscow 2002 focused the attention on these agents and their 
possible application as a counter-terrorist tool. In addition, today’s advancement in drug 
research and development together with growing knowledge and understanding of 
human physiology and how human mind works have increased the interest in ICAs. [2, 
pp. 5–6] 
The purpose of this thesis was to test the existing recommended operating procedures 
(ROPs, introduced in The Blue Book, Recommended Operating Procedures for 
Analysis in the Verification of Chemical Disarmament) for sample preparation, 
screening and identification of CNS acting chemical agents in environmental samples 
and to validate a method for determining fentanyl, a CNS acting drug with possible 
application as an incapacitant, in urine [4]. The candidate chemicals were selected for 
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the study and the availability of the reference chemicals was investigated. A review of 
literature on the candidate chemicals and methods for analyzing the substances was 
carried out. The analysis of fentanyl in urine was based on the review of existing 
literature.  The sample preparation and analysis of the environmental samples were 
conducted according to the ROPs. In addition, electron ionization (EI) mass spectra for 
the candidate chemicals were produced and the spectral data will be submitted to be 
evaluated and included in the OPCW Central Analytical Database (OCAD) in future.  
From different environmental sample matrices, wipe samples were selected for the 
ROP testing experiments. A wipe is an appropriate tool for collecting samples from 
various surfaces, such as, the inside of reactor vessels, containers and fume hoods. In 
addition, wipes can be used for sample collection when no apparent liquid or solid 
samples are available. For example, in United States wipe sampling of household 
surfaces is used for revealing methamphetamine contamination caused by clandestine 
drug laboratories [5, p. 23]. [6, pp. 39–40] 
The ROPs that are applied in the analysis of wipe samples are introduced in The Blue 
Book, Recommended Operating Procedures for Analysis in the Verification of Chemical 
Disarmament, published by University of Helsinki. These ROPs introduce the methods 
and guidelines to be followed in designated laboratories of the Organization for the 
Prohibition of Chemical Weapons (OPCW) or in laboratories applying for designation. 
The ROPs include guidelines, for instance, for preparation of different environmental 
sample matrices and for screening and identification of CWC-related chemicals. The 
Blue Book is edited by VERIFIN and the ROPs are regularly updated by the 
collaborating expert laboratories working with CWC-related chemicals. [4] 
2 Incapacitating chemical agents 
Incapacitating chemical agents can be defined as toxic chemicals that cause temporary 
incapacitation to humans or animals, but not usually death or permanent harm, differing 
from riot control agents (RCA) in longer duration of action [7, p. 5]. The definitions may 
vary depending on the context they are used in. In some contexts the ICAs have been 
described as “non-lethal” or “less-than-lethal” agents. According to some experts, ICAs 
should not be considered as non-lethal due to the fact that they can cause death in 
actual use. The lethality of ICAs is dependent on several factors, such as the actual 
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dose of the agent, the physiology of the victim and the availability of medical care and 
antidote. [2, p. 5] 
The CWC does not define the term incapacitating chemical agent. However, in the 
CWC ICAs are covered under the definition of “toxic chemicals”. The CWC Article II.2 
defines toxic chemicals as follows: 
 Any chemical which through its chemical action on life processes can cause 
death, temporary incapacitation or permanent harm to humans or animals. This 
includes all such chemicals, regardless of their origin or of their method of 
production, and regardless of whether they are produced in facilities, in munitions 
or elsewhere. 
This is a so-called general purpose criterion. 
There is a large variety of substances that can potentially be used as ICAs. Recently 
the research has focused on chemicals such as anesthetic agents, skeletal muscle 
relaxants, opioid analgesics, anxioltytics, antipsychotics, antidepressants and sedative-
hypnotic agents [8, p. 58]. Many of these chemicals are used in human or veterinary 
medicine as tranquilizing or anesthetic agents [8, p. 58]. The chemicals selected for 
this research were CNS acting drugs:  fentanyl, amphetamine and naloxone. Diazepam 
was also among the selected candidate agents but due to delivery problems of the 
reference chemical it was left outside of the ROP testing study. Fentanyl and diazepam 
are categorized as calmatives and amphetamine as a CNS stimulant [9, pp. 15–16][10, 
p. 612]. Naloxone works as an opioid antagonist [10, p. 605].  
2.1 Moscow hostage crisis 
The most prominent use of CNS acting drugs for counter-terrorist purposes was at the 
Dubrovka Theater in Moscow during the hostage crisis in 2002. The crisis began when 
Chechen militants, equipped with explosives, seized the Dubrovka Theater in Moscow 
taking over 800 hostages during a sold-out performance. The Russian Special Forces 
surrounded the theater. After a two-and-a-half day’s siege the Special Forces pumped 
a chemical aerosol into the building’s ventilation system and raided the theater. The 
chemical deployed to the theater hall rendered most of the hostages and terrorists 
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unconscious. Over 120 hostages and all of the terrorists died during the hostage crisis. 
[11] 
Most of the hostages killed in the raid died from the effects of the chemical. The 
medical personnel were not informed about the composition of the aerosol deployed to 
the concert hall and they were not able to offer adequate treatment for the victims. It is 
possible that by preparing the medical personnel and reserving enough antidote, such 
as naloxone, the casualties could have been minimized. Afterwards the Russian Health 
Minister stated that the chemical used in the raid was a fentanyl-based substance [12]. 
Traces of remifentanil and carfentanil (derivatives of fentanyl) were found in the 
clothing of British hostages [11]. [13, p. 20] 
2.2 Fentanyl 
Fentanyl (Figure 1) N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide, is a 
synthetic opioid, related to meperidine. The chemical and physical properties of 
fentanyl are listed in Table 1. Fentanyl was first synthesized by Paul Janssen in 1960 
[14]. It is a highly potent narcotic that is commonly used as a surgical anesthetic and 
for pain treatment (a therapeutic plasma concentration for analgesia is usually 1–2 
ng/ml and for anesthesia it is 10–20 ng/ml) [15]. Fentanyl has been reported to be 
approximately 250 times more potent than morphine [14]. 
 
Figure 1. Molecular structure of fentanyl. 
Table 1. Physical and chemical properties of fentanyl [16]. 
Properties Fentanyl Fentanyl-d5 Fentanyl citrate 
CAS Number 437-38-7 118357-29-2 990-73-8 
MW 336.47 341.50 528.59 
pKa 8.4 - - 
Melting point (oC) 83–84 - 149–151 
Partition coefficient (n-octanol/water) 860 - - 
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Fentanyl is a strong µ-opioid receptor agonist that has very rapid onset of action and a 
short duration of action [17]. In human body it has a half-life of 1-2 hours [10, p. 606]. 
Fentanyl has a wide range of side effects including respiratory depression, nausea, 
dizziness, vomiting, fatigue, headache, constipation, anemia and peripheral edema 
[15]. Due to the pharmacological properties of fentanyl and its derivatives (e.g. 
carfentanil), they have potential applications as incapacitating agents [9, p. 49]. 
There is a variety of methods developed for the determination and quantitation of 
fentanyl and its derivatives in human urine and blood by liquid chromatography-tandem 
mass spectrometry (LC–MS/MS) and gas chromatography-mass spectrometry (GC–
MS) [18][19][20][21]. A method for detection of fentanyls in wipe samples have also 
been reported [22]. A notable research, closely related to this study, is the analysis of 
fentanyls and their metabolites in clothing, urine and plasma of the survivors of the 
Moscow hostage crisis [11]. Riches et al. managed to find residues of carfentanil and 
remifentanil in the clothing samples taken from British hostages analyzed by LC–
MS/MS. The concentrations detected were lower than 0.5 ng/ml. 
2.3 Amphetamine 
Amphetamine (Figure 2), 1-phenylpropan-2-amine, is a synthetic substance that acts 
as central nervous stimulant. Chemical and physical properties of amphetamine are 
given in Table 2. In human body amphetamine mainly acts by releasing noradrenaline 
and dopamine. The effects of the drug are increased heart rate and blood pressure, 
locomotion stimulation and euphoria. With large doses stereotyped behavior occurs. 
The duration of action is approximately a few hours. [10, pp. 612–613] 
 
Figure 2. Molecular structure of amphetamine 
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Table 2. Physical and chemical properties of amphetamine [16]. RT refers to room temperature. 
Properties Amphetamine Amphetamine sulphate 
Amphetamine 
phosphate 
CAS Number 300-62-9 60-13-9 139-10-6 
MW 135.21 368.49 233.20 
Melting point  (oC) Mobile liquid at RT above 300 - 
Boiling point (oC) 200–203 - - 
Amphetamine and its derivatives have therapeutic use in treatment of narcolepsy and 
attention deficit-hyperactivity disorder (ADHD) in children. Clinical use of 
amphetamines is very limited due to its many unwanted effects. The main importance 
of amphetamines is in drug abuse. US Army Chemical Corps has reported that 
psychochemicals, such as phenethylamines, could potentially be used as 
incapacitating agents [3, p. 4]. [10, p. 614] 
The analysis of amphetamines by GC usually includes derivatization prior to analysis. 
This is not mandatory but it improves chromatographic properties and detectability of 
amphetamines. For example, analyses that include silylation of amphetamine with 
BSTFA and MTBSTFA have been described [23, p. 76][24]. Several methods for 
detecting amphetamine and related compounds by LC–MS/MS have also been 
developed, including a method for detecting amphetamine in wipe samples [25][26]. 
Free base of amphetamine is a liquid and volatile compound at room temperature. This 
should be taken into account in sample preparation because evaporating the sample to 
dryness can cause significant loss of the analyte. [23, p. 75] 
2.4 Naloxone 
Naloxone (Figure 3), (5Į)-4,5-epoxy-3,14-dihydroxy-17-(2-propen-1-yl)morphinan-6-
one, is a pure opioid antagonist that has affinity for all of the three opioid receptors: µ-, 
ț- and į-receptors. The physical and chemical properties of naloxone are listed in 
Table 3. Naloxone blocks the action of both endogenous opioid peptides and 
morphine-related drugs. It is rapidly metabolized by liver and the duration of action is 
from 2 to 4 hours. It is clinically used in treatment of respiratory depression caused by 
opioid (e.g. morphine) overdose. Naloxone has little effects when given on its own, 
whereas it produces a rapid reversal of the effects of opioids. Naloxone does not have 
applications as an incapacitating agent as such, but it can be used as an antidote for 
opioid incapacitating agents [3, p. 15]. [10, p. 605] 
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Figure 3. Molecular structure of naloxone. 
Table 3. Physical and chemical properties of naloxone [16]. 
Properties Naloxone Naloxone hydrochloride 
CAS Number 465-65-6 357-08-4 
MW 327.27 363.84 
Melting point (oC) 184 200–205 
Several methods for detecting naloxone from different biological matrices by LC–
MS/MS have been reported [27][28]. Methods for detecting naloxone by GC–MS were 
not found in the review of literature. However, a method for analyzing naltrexone (a 
very similar compound to naloxone) by GC–MS using naloxone as internal standard 
was found. This method included silylation of naloxone and naltrexone prior to analysis. 
Due to keto-enol tautomerism that occurs on naloxone and naltrexone, these 
compounds have three potential hydroxyl groups where the silyl group can attach. 
Because of the keto-enol tautomerism and incomplete silylation, it is possible that 
naloxone and naltrexone form several different products when silylated. [29] 
3 Sample preparation techniques 
3.1 Silylation 
Silylation is a derivatization technique where an active hydrogen bound to a 
heteroatom is replaced with a silyl group. Usually the compound is converted to a 
trimethylsilyl (TMS) derivative but also other derivatives can be used. For instance, a 
tert-butyldimethylsilyl (TBDMS) group is often used for substituting the hydrogen. 
These silylated compounds are generally less polar, more stable and more suitable for 
GC. The formation of a TMS derivative can be written as in Figure 4. [30, p.545] 
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Figure 4. The formation of a TMS derivative. The active hydrogen of the compound Y-H is replaced with 
the TMS group of the silylation reagent TMS-X [30, p. 546]. 
There is a variety of different reagents for silylation and aprotic solvents that can be 
used as medium. In this thesis, BSTFA (N,O-bis(trimethylsilyl)-trifluoroacetamide, 
Figure 5) was used as silylating reagent and high purity acetonitrile was used as 
solvent. BSTFA can silylate several different functional groups, including primary 
amines and hydroxyl groups [30, p. 553]. Therefore, it was presumed to be valid 
reagent for silylating amphetamine and naloxone. Fentanyl does not contain any 
functional groups that would react with the silylation reagent.  
 
Figure 5. Molecular structure of BSTFA. 
3.2 Solid phase extraction 
Solid phase extraction (SPE) is a common sample preparation procedure used for 
cleanup and concentration of liquid samples. A certain amount of finely divided porous 
solid material is used for retaining the analytes of interest or the interfering compounds 
from a sample solution. The solid phase (from 50 mg to 10 g) is usually packed into a 
small column, cartridge or disc. In this thesis, SPE was employed to clean up the urine 
sample. The cleanup was based on the retention of the analyte and elution of the 
interfering compounds. Figure 6 shows the extraction procedure schematically. The 
diluted urine sample was introduced into the cartridge (A). The analytes retain on the 
solid phase while the solvent and some of the interferences drain from the cartridge. 
The cartridge is washed with wash solution in order to remove interferences from the 
solid phase (B). Finally the analytes are eluted from the cartridge using appropriate 
solvent (C). The eluate is collected for an analysis. [30, p. 341] 
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Figure 6. SPE cleanup with analyte retention (A) followed by washing (B) and elution (C) [30 p. 341]. 
4 Analytical methods 
4.1 Gas chromatography 
Gas chromatography (GC) is an analytical separation technique used to analyze 
volatile organic compounds in gaseous phase. The separation of the substances relies 
on different partition behavior of components between two phases: a gaseous mobile 
phase and a stationary phase. The mobile phase is an inert gas (often He) that carries 
the analytes into the column. The stationary phase is usually a thin film of liquid or 
polymer coated inside the tubular column. The carrier gas transports the gaseous 
sample inside the column where separation occurs. The separated compounds are 
detected when exiting the column. [31, pp. 565–566, 574, 579] 
10 
  
4.1.1 Injector 
A volatile liquid or gaseous sample is introduced to the high-temperature injector where 
it vaporizes. The analyzed molecules have to be volatile and inert enough not to 
decompose in high temperature. The injection can be operated in split or splitless 
mode. Split injection is preferred when analytes constitute more than 0.1 % of the 
sample. For trace analysis, splitless injection is more appropriate. [31, pp. 577–578] 
In this thesis, splitless injection was applied due to small concentration of the analytes 
of interest. In splitless injection (Figure 7) a relatively large volume (~2 µl) of liquid 
sample is injected with syringe through a rubber septum into a heated glass liner. The 
split vent is held closed. The liquid sample evaporates in the liner and the sample 
vapors are transported into the column by carrier gas.  The sample spends relatively 
long time (~1 min) in the injection port. Slow flow of the septum purge cleans the 
septum and removes any vapors that escape the glass liner. After the injection the split 
vent is opened and the injector is quickly flushed. [31, p. 578] 
 
Figure 7. Schematic representation of splitless injection into an open tubular column. 
The sample molecules are introduced into the column during the entire splitless time. 
This could cause an unacceptable broadening of the peaks in the chromatogram. The 
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broadening is avoided by using suitable initial column temperatures. When setting the 
temperature below the solvent’s boiling point, the solvent and other solutes condense 
at the beginning of the column and the solvent slowly evaporates. This technique is 
called solvent trapping. A focusing mechanism called cold trapping can be applied to 
solutes with high boiling point. These solutes condense at the beginning of the column 
while solvent and other lower boiling components are eluted by the carrier gas. 
Chromatography is then initiated by raising the column temperature. [31, p. 578] 
4.1.2 GC Column 
The majority of the columns used in GC are long, narrow wall coated open tubular 
(WCOT) columns. The columns are usually made of fused silica coated with polyimide. 
Typical column dimensions are 30 m length and 0.1 to 0.5 mm internal diameter.  The 
stationary phase is often a 0.25 µm thick film bonded to the inner wall of the column. 
Polysiloxanes are common materials used as stationary phases. [31, pp. 566-567, 569] 
The column is located in a column oven. The oven can be operated in temperature 
programming in which the temperature is usually set to increase during the run. High 
temperature increases the vapor pressure of analytes and decreases retention time of 
late-eluting analytes making shorter run times possible. Temperature programming can 
also be utilized to achieve sharper peaks for late-eluting compounds. [31, pp. 573-574] 
4.1.3 Electron ionization 
Only charged molecules can be detected with mass spectrometer. In order to detect 
neutral molecules exiting the GC column, the gas phase molecules are converted into 
charged ions and fragments by electron ionization (EI). Molecules from the GC column, 
connected directly to the mass spectrometer, enter the ion source. A beam of electrons 
emitted from a hot filament is accelerated through 70 V. These energetic electrons 
collide with neutral molecules (M) in gas phase dislodging an electron from the 
molecules and forming molecular ion M+·. Usually the M+· has enough internal energy to 
decompose into smaller fragments. In the ion source, the charged fragment ions are 
directed to the mass separator by a charged repeller. [31, pp. 503-504] 
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The ionization energy has a major effect on the fragmentation of the molecule and 
therefore on the mass spectrum. The reference EI mass spectra that exist in mass 
spectral libraries, such as OCAD, Wiley and NIST (National Institute of Standards and 
Technology), are recorded using the electron energy of 70 eV [32, p. 142]. In this 
thesis, ionization energy of 70 eV is used in order to obtain reproducible fragmentation 
pattern for compounds and to produce mass spectra that are comparable with the 
library spectra. [31, p. 505] 
4.2 High-Performance Liquid chromatography 
High-performance liquid chromatography (HPLC) is an analytical technique that uses 
high pressure to force solvent containing sample mixture through a closed column 
packed with fine particles. The chromatographic separation of the compounds relies on 
different partition behavior of components between two phases: a liquid mobile phase 
and a stationary phase. The mobile phase is liquid solvent (e.g. water, methanol, 
acetonitrile) and the stationary phase is either solid or liquid. [31, p. 596] 
The basic instrumentation of the HPLC includes mobile phase reservoirs, pumps, an 
injector, a column and a detector. Liquid eluent is pumped from the eluent inlet at 
stable flow up to 2 ml/min. A loop injector is very commonly used injector type for 
HPLC. The liquid sample is introduced into a loop with a nominal volume. The pumps 
maintain constant flow rate through the HPLC system and the injection is completed by 
moving a rotating switch. This directs the flow through the loop and the liquid sample is 
flushed among the mobile phase into the column. The separation of the compounds 
occurs in the column and the separated compounds are detected after exiting the 
column. A method that uses a mobile phase of constant composition during entire 
elution is termed isocratic elution. In gradient elution the composition changes during 
the analysis. The rate at which the composition is changed has a major impact on the 
separation of the compounds. [33, pp. 10–12] 
4.2.1 HPLC Column 
A typical HPLC column consists of fine particles packed tightly into a steel reinforced 
tube. These particles are employed as the stationary phase. The stationary phase can 
be either solid, such as silica particles, or immiscible liquid bonded to a solid support.  
13 
  
HPLC column dimensions are typically 5–30 cm length and 1–5 mm inner diameter. 
The particle size of the stationary phase column is usually from 1.7 to 5 µm. The 
efficiency of a column can be increased by decreasing the stationary phase particle 
size. When using smaller particle size, higher pressure is required but improvement in 
resolution is achieved. Alternatively, the use of smaller particles shortens the run time 
while the same resolution is maintained. [31, pp. 596–602] 
In this thesis, the HPLC analyses were carried out with hydrophobic reversed-phase 
(RP) column. The RP column stationary phase consists of nonpolar hydrocarbon 
chains bonded covalently to the silica surface. The very commonly used stationary 
phase is an octadecyl (C18) alkyl group bonded to the silica surface (Figure 8). 
Interactions with nonpolar stationary phase cause longer retention times for nonpolar 
molecules while polar molecules elute more readily with the mobile phase. In RP 
chromatography less peak tailing occurs compared to normal-phase chromatography 
because the RP stationary phase has fewer sites that can strongly adsorb molecules 
and cause peak tailing. [31, p. 603] 
 
Figure 8. An octadecyl alkyl group attached to the silica surface [31, p. 600]. 
4.2.2 Electrospray ionization 
Solvent in LC creates a significant volume of gas when vaporizing. Most of this gas 
must be removed before the analytes are introduced into the mass spectrometer. 
Electrospray ionization (ESI) is a technique in which protonated or deprotonated 
molecules are transferred from liquid solvent into gaseous phase and the excess 
gaseous eluent is disposed. ESI is a soft ionization technique that causes little 
fragmentation of analytes. It can be operated in both positive and negative mode. In 
positive mode, protonated molecules ([M+H]+) or other adduct ions (e.g. [M+Na]+) are 
formed and in negative mode, deprotonated ([M-H]-) molecules are formed. [31, pp. 
519–521] 
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Eluent from the HPLC enters a metal capillary needle at relatively low flow rate. A high 
voltage (2–6 kV) is applied to the capillary needle relative to the spray chamber. Liquid 
enters the spray chamber where a strong electric field and a coaxial flow of N2 sheath 
gas disperses the solvent into a fine aerosol of highly charged droplets. Nitrogen drying 
gas evaporates the solvent diminishing the droplets until the repulsive force of charged 
molecules equals the cohesive force of surface tension. The droplets break up into 
smaller droplets which evaporate and release the charged molecules into the gaseous 
phase. The analytes pass through a sampling cone or a heated capillary and enter the 
mass analyzer. A schematic representation of ESI is shown in Figure 9. [34] 
 
Figure 9. Schematic representation of ESI [34.]. 
4.3 Mass spectrometry 
Mass spectrometer (MS) is a commonly used detector in chromatography that provides 
both quantitative and qualitative information on molecules [31, p. 519]. Mass 
spectrometry makes identification of compounds possible with a high degree of 
confidence. Also, compounds that have similar retention characteristics and are not 
fully resolved chromatographically can be differentiated by their mass spectra [33, p.3]. 
In mass spectrometry charged molecules or fragments of molecules are accelerated in 
vacuum by an electric field and separated according to their mass and charge (mass-
to-charge ratio, m/z). Charged fragments of a compound with different m/z are 
15 
  
analyzed in the detector and a mass spectrum representing the detector response vs. 
m/z is obtained [31, p. 502]. 
4.3.1 Quadrupole mass spectrometer 
In this thesis, quadrupole mass spectrometer was used. It is a common mass separator 
with ability to scan ions fast using low voltages which makes it suitable detector for 
chromatography. Figure 10 shows the structure of a quadrupole mass separator. Four 
parallel metal rods are applied with a constant (DC, direct current) voltage and a radio-
frequency (RF) alternating voltage. Ions arriving from the ionization chamber migrate 
between the rods towards the detector. The applied voltages affect the trajectory of the 
charged ion. For given voltages, only ions of a particular m/z (resonant) reach the 
detector while others (nonresonant) collide with the rods. By rapidly and systematically 
varying the voltages, ions of different m/z reach the detector and a mass spectrum is 
produced. The size of the ions detected can be as high as 4000 m/z units [31, p. 514]. 
[33., p.41] 
 
Figure 10. Structure of a quadrupole mass separator [31, p. 513]. 
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4.3.2 Triple quadrupole mass spectrometer 
Triple quadrupole mass spectrometer is a tandem mass spectrometer (MS/MS) where 
two mass separators are connected in series. The triple quadrupole mass spectrometer 
consists of two quadrupole mass separators and a quadrupole employed as a collision 
cell between them. The mass selective detection system can be operated in multiple 
reaction monitoring (MRM) that provides very sensitive and selective method for 
detecting targeted molecules: as low as parts per trillion levels can be achieved [31, p. 
524]. The schematic representation of the triple quadrupole mass spectrometer and the 
principle of MRM are shown in Figure 11. 
 
Figure 11.  Schematic representation of a triple quadrupole mass spectrometer and the principle of MRM  
[31., p. 525]. 
In MRM, a mixture of ions arrives to quadrupole Q1 from the ion source. Ions with 
selected m/z, precursor ions, are allowed to pass the quadrupole. In Q2 precursor ions 
are collided to N2 or Ar at very low pressure (~10-5 to 10-3 Torr). This produces 
characteristic molecule fragments called product ions. These ions are introduced to Q3 
and the product ions of selected m/z pass the quadrupole and reach the detector which 
measures the quantity of the ions. [31, p. 524] 
5 Experimental 
5.1 Safety measures 
Normal laboratory safety procedures were followed when working with hazardous 
chemicals. Due to high potency and chemical stability of fentanyl, extra attention was 
paid when handling the substance. Garg et al. reported that in their studies no 
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applicable and effective treatment to degrade fentanyl using light, base, heat or 
oxidation was found [35]. In this experimental all the equipment that had been in 
contact with the analytes was rinsed with 10 % KOH in ethanol decontamination 
solution. Decontamination solution waste was then collected into a plastic vessel and 
sent to the local waste disposal company for further processing.  
5.2 Purchase of the reference standard chemicals 
The substances observed in this thesis are used as pharmaceutical drugs and some of 
them have also importance in drug abuse. Amphetamine, fentanyl and diazepam are 
classified as narcotic drugs in Finnish narcotic legislation (543/2008). The Finnish 
Narcotic Act (373/2008) prohibits production, manufacture, import to the territory of 
Finland, export from the territory of Finland, distribution, trade, handling, possession of 
these above-mentioned narcotic drugs. Deviations from the prohibitions are allowed, 
for example, for research purposes. [36] 
In order to purchase reference standards for amphetamine, fentanyl and diazepam, 
licenses to import and to handle these narcotics were applied from Finnish Medicines 
Agency (Fimea). It should be noted that each compound to be handled and imported 
has to be specified in the application, including different salt forms of the substance. 
For example, a license to handle or import fentanyl covers only fentanyl free base, not 
fentanyl salts (e.g. fentanyl citrate). 
5.3 Chemicals and standards 
The chemicals and reference standards used in the experimental are listed in Table 4. 
0.2 M acetate buffer (pH 4) used in the urine analysis was prepared by weighing 3.775 
g of ammonium acetate and dissolving it into 200 ml of ultrapure water. pH was 
adjusted to 4 by adding acetic acid into the solution. Water was added to obtain final 
volume of 250 ml. All the spiking solutions were prepared in methanol at concentrations 
described in the sample preparation section. 
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Table 4. Chemicals and standard used in the experimental. 
Chemicals Use Manufacturer Purity 
Acetone Solvent Sigma Aldrich ш99.8 % 
Acetonitrile Solvent BDH ш99.8 % 
Dichloromethane Solvent VWR HPLC grade 
Methanol Solvent VWR HPLC grade 
Ultrapure water Solvent in-house 18.2 µS/cm (conductivity) 
Ammonium acetate Acetate buffer Merck pro analysis 
Formic acid LC eluent Merck 98 - 100 % 
Acetic acid Acetate buffer Merck 99.8 % 
BSTFA Silylation reagent Alltech - 
Reference standards Solvent / volume Manufacturer Concentration 
Fentanyl Methanol / 1 ml Sigma Aldrich 1 mg/ml 
Fentanyl-d5 Methanol / 1 ml Sigma Aldrich 100 µg/ml 
Amphetamine Methanol / 1 ml Sigma Aldrich 1 mg/ml 
Naloxone Methanol / 1 ml Sigma Aldrich 1 mg/ml 
Diazepam Methanol / 1 ml Sigma Aldrich 1 mg/ml 
5.4 Materials 
The materials used in the experimental are listed in Table 5. In the sample preparation 
TurboVap LV Concentration Workstation was used for concentrating and Branson 3210 
Ultrasonic Cleaner for sonicating the samples. The ultrapure water was drawn from 
Milli-Q (Merck Millipore, 0.22 µm filter) filter apparatus. 
Table 5. Materials used in the experimental 
Material Manufacturer Specifications 
SPE cartridge Oasis HLB, volume 3 ml, 60 mg sorbent per cartridge 
Cotton swab - Non-sterile wood hospital applicators, 150 mm x 2.2 mm 
Cotton wipe TexWipe TX306, 100 % cotton, 15 cm x 15 cm 
Filter paper GE Healthcare Whatman 50, hardened, diam. 90 mm 
Disposable filter Millex 0.2 µm, low protein binding hydrophilic (PTFE) membrane 
5.5 Urine samples 
Blank and standard samples were prepared into a pool of fentanyl-free urine collected 
from four healthy donors. The authentic urine sample was obtained from a patient who 
was given fentanyl intravenously prior to a surgical procedure. The sample was taken 
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approximately 4 hours after the injection. The authentic urine sample and pooled 
fentanyl-free urine were stored in the freezer at - 20 oC.  
5.6 Instrumentation 
5.6.1 GC–MS instrumentation 
The GC–MS instrumentation and method parameters are listed in Table 6. Method 1 
corresponds to the recommended GC conditions used for screening CWC-related 
chemicals and measuring retention indices for the OCAD [37]. This method was 
applied in the screening experiments. The data acquisition was operated on full scan 
mode in the method 1. Method 2 was applied when measuring the recoveries of the 
analytes from the wipe samples. The data acquisition was operated on SIM (selected 
ion monitoring) mode in the method 2 (the monitored ions are given in Table 7). 
Method 2 was set to increase the oven temperature fast after elution of amphetamine-
TMS (retention time 12.70 min). This was done in order to improve the peak shapes 
and to reduce retention times of the late-eluting compounds fentanyl and naloxone-
3TMS. Except for the data acquisition mode and temperature program, the methods 1 
and 2 were identical. 
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Table 6. GC–MS instrumentation and method parameters. 
GC–MS instrumentation  
GC Agilent Technologies 6890N 
MS Agilent Technologies 5975N 
Column DB-5MS, 30 m x 250 µm x 0.25 µm 
Method Method 1 Method 2 
Injection mode splitless splitless 
Splitless time  1 min 1 min 
injection volume 1 µl 1 µl 
Injection temperature 250 oC 250 oC 
Carrier gas He He 
Flow pressure 0.487 bar 0.487 bar 
Temperature program 1 min at 40 oC 1 min at 40 oC 
 10 
oC/min to 300 oC 10 oC/min to 160 oC 
 5 min at 300 
oC 30 oC/min to 300 oC 
  10 min at 300 
oC 
MS Method 1 Method 2 
Ionization EI EI 
Electron energy 70 eV 70 eV 
Tranfer line temperature 290 oC 290 oC 
Ion source temperature 230 oC 230 oC 
Data acquisition mode Full scan SIM 
Scan range 40 - 600 m/z See Table 7 
 
Table 7. The ions monitored in SIM. 
Analyte Quantifier ion, Q (m/z) Qualifier ions, q (m/z) 
Fentanyl 245 146, 189 
Amphetamine-TMS 91 116, 192 
Naloxone-3TMS 438 528, 543 
5.6.2 LC–MS/MS instrumentation 
The LC–MS/MS instrumentation and method parameters are listed in Table 8. Same 
LC parameters were used in both wipe and urine analysis. Optimized MRM conditions 
for each precursor and product ion are given in Table 9. The MRM conditions were 
optimized by infusing 10 µg/ml analyte of interest in water into the ESI source and 
adjusting the cone voltages and collision energies manually.  
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Table 8. LC–MS/MS instrumentation and method parameters. 
LC-MS instrumentation 
LC Waters Acquity UPLC H-class 
Column Waters Acquity UPLC BEH C18 1.7 µm, 2.1 x 100 mm 
Mass spectrometer Waters TQD Xevo TQD 
LC parameters   
Injection volume 5 µl 
Flow rate 0.6 ml/min 
Column temperature 60 oC 
Mobile phase A 0.1 % HCOOH in H2O (v/v) 
Mobile phase B 0.1 % HCOOH in MeOH (v/v) 
Gradient 1 % B and 99 % A for 0.6 min 
 From 1 % to 100 % (B) in 0.6 - 2.3 min 
 100 % B for 1.7 min 
Total run time 5.5 min 
MS parameters   
Ionization mode  ESI+ 
Capillary voltage 3.5 kV 
Source temperature 120 oC 
Desolvation gas N2 
Desolvation gas flow 1000 l/h 
Desolvation temperature 500 oC 
Collision gas Argon 
Mass resolution 0.75 amu 
 
Table 9. MRM transitions and conditions for amphetamine, fentanyl, fentanyl-d5 and naloxone. Q refers to 
quantifier ion and q to qualifier ion. 
Analyte Precursor ion  (m/z) 
Cone voltage  
(V) 
Product ions 
(m/z) 
Collision energy  
(V) 
Amphetamine 136 40 
119 (q) 15 
91 (Q) 10 
Fentanyl 337 40 
216 (q) 25 
105 (q) 35 
188 (Q) 25 
Fentanyl-d5 342 35 
105 (q) 35 
188 (Q) 25 
Naloxone 328 35 212 (q) 40 
310 (Q) 20 
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6 Sample preparation 
6.1 Preparation of wipe samples 
Preparation of the wipe samples was conducted according to the ROP of wipe samples 
[38]. The wipes were extracted successively with organic solvent and water. Because 
of the different size of the wipes, the extraction and spiking volumes varied depending 
on the wipe. The wipe-specific spiking and extraction volumes are shown in Table 10. 
Three different wipe materials (cotton swab, Whatman filter paper and cotton wipe) and 
two different organic extraction solvents (acetone and dichloromethane) were used in 
the ROP testing experiments. Acetone and dichloromethane were selected for the 
study because they are considered as possible non-polar organic extraction solvents in 
the ROP [38]. 
Figure 12 shows the flowchart of the sample preparation process. In total 6 sample 
batches were prepared and analyzed. One batch of samples included six replicate 
standard samples spiked with fentanyl, naloxone and amphetamine and two matrix 
blanks. For recovery study, one matrix blank extract was spiked with the analytes in the 
end of the sample preparation. 
Table 10. Sample preparation specifications for different wipe materials. 
 
Cotton swap Whatman filter  paper Cotton wipe 
V (spiking solution) 100 µl 100 µl 200 µl 
m (analyte) / wipe 4 µg 4 µg 8 µg 
V (extraction vial) 8 ml 20 ml 100 ml 
V (extraction solvent) 2 x 2.5 ml 2 x 10 ml 2 x 50 ml 
V (volumetric flask) 5 ml 20 ml 100 ml 
V (aliquot prepared) 1 ml 5 ml 10 ml 
V (post-spiked spiking solution) 20 µl 25 µl 20 µl 
c (analytes in the final sample with 100 % 
recovery) 1.6 µg/ml 2.0 µg/ml 1.6 µg/ml 
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Figure 12. Sample preparation flowchart for wipe samples. 
The wipe was inserted into a glass vial. The Whatman filter paper and the cotton wipe 
were folded multiple times before placing into the vial. The wooden rod of the cotton 
swab was cut off and the cotton wad was placed into the vial. The wipe was wetted 
with 1 ml of organic extraction solvent (except for cotton swab which was not wetted) 
and spiked with spiking solution (40 µg/ml fentanyl, naloxone and amphetamine in 
methanol). The wipe was allowed to dry for 60 min. The first portion of organic 
extraction solvent was added into the vial and the sample was sonicated for 3 min. 
After sonication the extraction solvent was transferred into a volumetric flask. The 
extraction procedure was repeated with another portion of organic extraction solvent. 
The volumetric flask was filled with solvent. The excess extraction solvent was allowed 
to evaporate from the wipe. After evaporation, the wipe was extracted with two portions 
of ultrapure water in a similar way to the organic solvent. 
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Organic fraction  
For LC–MS/MS analysis, an aliquot of the organic extract was transferred into a test 
tube with screw cap and evaporated to dryness under nitrogen flow in TurboVap at 40 
oC. Immediately after evaporation the residue of the aliquot was reconstituted in 500 µl 
of ultra-pure water. One matrix blank extract was spiked with 40 µg/ml spiking solution 
for recovery study. The samples were filtered with 0.2 µm disposable filter and 
analyzed by LC–MS/MS.  
For GC–MS analysis, an aliquot of the organic fraction was evaporated to dryness in 
TurboVap at 40 oC. The residue of the aliquot was reconstituted in 200 µl of BSTFA 
and 200 µl of acetonitrile (one matrix blank extract was spiked with 40 µg/ml spiking 
solution prior to evaporation to dryness). The sample was incubated at 60 oC for 30 
min. The sample was allowed to cool and 100 µl of dichloromethane was added prior to 
analysis by GC–MS. 
Water fraction 
Two aliquots of the aqueous extract were prepared in a similar way to the organic 
aliquots. For GC–MS analysis, an aliquot was evaporated to dryness and silylated with 
BSTFA as described before. For LC–MS/MS analysis, an aliquot was concentrated into 
final volume of 500 µl and filtered with 0.2 µm disposable filter.  
6.2 Preparation of urine samples 
The urine standard and blank samples were prepared into pooled fentanyl-free urine. 
500 µl of urine was spiked with 20 µl of isotope labeled internal standard (IS) spiking 
solution (250 ng/ml fentanyl-d5 in methanol). Calibrators and quality control samples 
(QCs) were spiked with fentanyl spiking solution into desired concentrations (Table 11). 
The SPE procedure used to clean the samples was based on the method of Wang & 
Bernert with some minor modifications [20]. 
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Table 11. Spiking solutions and volumes for standard samples. 
Standard sample c (ng/ml) V (fentanyl-d5 250 ng/ml spiking solution) 
V (fentanyl 50 ng/ml 
spiking solution) 
V (fentanyl 500 ng/ml 
spiking solution) 
Calibrator 0 20 µl - - 
Calibrator 0.5 20 µl 5 µl - 
Calibrator 1 20 µl 10 µl - 
Calibrator 5 20 µl 50 µl - 
Calibrator 10 20 µl - 10 µl 
Calibrator 25 20 µl - 25 µl 
Calibrator 50 20 µl - 50 µl 
QC 1 20 µl 10 µl - 
Recovery standard 1 20 µl (post-spiked) 10 µl - 
Recovery standard 25 20 µl (post-spiked) - 25 µl 
The urine was diluted with 500 µl of 0.2 M ammonium acetate buffer (pH 4). The 
mixture was vortexed and let to equilibrate for 30 min. After equilibration the sample 
was loaded into an OASIS HLB cartridge preconditioned with 1 ml of methanol and 1 
ml of water, respectively. The sample was washed with 1 ml of 20 % (v/v) methanol in 
water. Excess washing solution was expelled from the cartridge. Fentanyl was eluted 
from the cartridge with 1 ml of methanol. The eluate was evaporated to dryness under 
nitrogen flow in TurboVap at 40 oC. The residue was dissolved in 200 µl of 0.1 % (v/v) 
formic acid in water, filtrated with 0.2 µm disposable filter and analyzed by LC–MS/MS.  
The validation experiments were conducted in four days. Three calibration curves were 
prepared each day, except for the last day when only two calibration curves were made 
for the recovery study. The seven point calibration curves were prepared at 
concentration levels of 0, 0.5, 1, 5, 10, 25 and 50 ng/ml. To determine extraction 
recovery three replicate samples were prepared by spiking pooled urine (with no IS 
added) with fentanyl at concentrations of 1 ng/ml and 25 ng/ml. The internal standard 
was added after extraction prior to evaporation to dryness. These recovery standards 
were quantified against normally prepared calibration curves. 
Among each calibration batch a urine blank with no IS added and a solvent blank 
(made in water instead of urine) were analyzed. In addition, a QC sample at the 
concentration of 1 ng/ml was prepared each day. This QC was analyzed before, 
between and after each calibration batch in order to see if any variation in results 
occurs. The authentic samples were analyzed during the validation experiments. In 
total seven replicate samples were prepared from the urine of the surgical patient and 
analyzed. 
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7 Results and discussion 
7.1 Mass spectra  
7.1.1 EI mass spectra 
One of the purposes of this thesis was to produce EI mass spectra for the selected 
candidate chemicals and submit the spectral data to be evaluated and included in the 
OCAD. The standard samples were analyzed by GC–EI–MS and the mass spectra 
were extracted with AMDIS software. There are certain requirements for the conditions 
under which the spectral data has to be recorded. The lowest recorded mass should be 
m/z 40 or lower and the highest at least 50 m/z above the molecular weight of the 
measured compound. The mass spectrum has to contain the peaks with intensity of 0.1 
% or higher from the base peak. The EI mass spectra were produced for 
amphetamine-TMS, naloxone-3TMS, naloxone-TMS, fentanyl, fentanyl-d5, and 
diazepam. Appendix 1 presents the hard copy of the accompanying information for the 
mass spectra to be submitted to the OCAD. 
The mass spectra of TMS derivatives of amphetamine (Figure 13) and naloxone 
(Figure 14) show abundant peaks at m/z 73. This peak corresponds to a TMS cation 
which is very commonly found on mass spectra of the TMS derivatives. Due to poor 
selectivity of the fragment, it was not used as quantifier or qualifier ion. Fragment ion 
M–15, which is generated by the loss of methyl from the TMS groups, is shown at m/z 
192 and at m/z 528 in the amphetamine-TMS and naloxone-3TMS mass spectra, 
respectively. [30, p.562] 
The peak at m/z 91 in amphetamine-TMS mass spectrum corresponds to tropylium ion 
or benzylic cation. The base peak at m/z 116 results probably from the loss of 
methylbenzene. Naloxone-3TMS produced a large variety of fragments with relatively 
low abundances. The ions with high m/z (m/z 543, 528 and 438) were selected for SIM 
due to better selectivity of large fragments. In addition to naloxone-3TMS, three other 
products were formed in silylation of naloxone with BSTFA. This was due to keto-enol 
tautomerism and incomplete silylation of the hydroxyl groups (see paragraph 2.4.). The 
total ion chromatogram (TIC) of a silylated naloxone standard showing the presence of 
multiple silylation products of naloxone is presented in Appendix 2. 
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Figure 13. GC–EI–MS full scan mass spectrum of amphetamine-TMS (MW=207). 
 
Figure 14. GC–EI–MS full scan mass spectrum of naloxone-3TMS (MW=543). 
The base peak at m/z 245 and 250 in fentanyl (Figure 15) and fentanyl-d5 (Figure 16) 
mass spectra are proposed to represent fragments generated by the loss of 
methylbenzene. The mass spectrum of diazepam (Figure 17) show base peak at m/z 
256 which results from the elimination of CO molecule. The peak formed by the loss of 
chlorine from the fragment m/z 256 is present at m/z 221. The peak at m/z 283 
corresponds to loss of a hydrogen radical from the molecular ion. [39] 
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Figure 15. GC–EI–MS full scan mass spectrum of fentanyl (MW=336). 
 
Figure 16. GC–EI–MS full scan mass spectrum of fentanyl-d5 (MW=341). 
 
Figure 17. GC–EI–MS full scan mass spectrum of diazepam (MW=284). 
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7.1.2 ESI product ion mass spectra 
ESI product ion mass spectra were recoded for fentanyl, fentanyl-d5, amphetamine and 
naloxone with LC–MS/MS. The analytes were ionized on positive ESI and the MS/MS 
was operated on product ion scan. The proposed structures of the product ions and the 
neutral losses are given in Table 12. 
Product ion mass spectra of both fentanyl and fentanyl-d5 (Figures 18 and 19) show 
two major peaks at m/z 188 and 105. The [M+H]+ can be seen at m/z 337 and 342 for 
fentanyl and fentanyl-d5, respectively. The ion at m/z 188 is formed by the loss of N-
phenylpropanamide and the ion at m/z 105 results from the loss of piperidine [40]. 
Fentanyl-d5 showed a product ion at m/z 221 which is 5 units higher than 
corresponding product ion in the fentanyl spectrum (m/z 216). This indicates that the 
product ion contains the phenyl group labeled with 5 deuterium atoms. The structures 
of product ions at m/z 188, 216 and 221 are adopted from the study of Wang & Bernert 
[20].  
 
Figure 18. LC–ESI–MS/MS product ion mass spectrum of fentanyl produced with collision energy of 25 V. 
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Figure 19. LC–ESI–MS/MS product ion mass spectrum of fentanyl-d5 produced with collision energy of 25 
V. 
The product ion mass spectrum of naloxone (Figure 20) shows the base peak at m/z 
310 which results from the loss of water. This product ion was selected as quantifier 
due to high intensity, although ROP doesn’t recommend fragments formed by the loss 
of water to be used in MRM [41]. The peak at m/z 328 represents [M+H]+ ion  of  
naloxone. Naloxone produced a large number of different product ions with low relative 
abundances. 
 
Figure 20. LC–ESI–MS/MS product ion mass spectrum of naloxone produced with collision energy of 25 
V. 
The product mass ion spectrum of amphetamine (Figure 21) shows two major peaks at 
m/z 119 and 91. The weak peak of [M+H]+ ion can be seen at m/z 136. The fragment 
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ion m/z 119 corresponds to a neutral loss of ammonium from molecular ion of 
amphetamine. The fragment ion at m/z 91 is proposed to represent benzyl cation or 
tropylium ion C7H7+ resulting from loss of ethylene.  
 
Figure 21. LC–ESI–MS/MS product ion mass spectrum of amphetamine produced with collision energy of 
15 V. 
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Table 12. [M+H]+ ions of fentanyl, fentanyl-d5, naloxone and amphetamine and proposed structures of 
their product ions and neutral losses. 
Analyte [M+H]+ Product ion Neutral loss 
Fentanyl 
 
 
 
 
[M+H]+ = 337 
 
m/z 
216 
 
121 
amu 
 
m/z 
188 
 
149 
amu 
 
m/z 
105 
 
85 
amu 
Fentanyl-d5 
  
  
 
 
[M+H]+ = 342 
 
m/z 
221 
 
121 
amu 
 
m/z 
188 
 
154 
amu 
 
m/z 
105 
 
85 
amu 
Naloxone 
  
 
[M+H]+ = 328 
 
[C19H20NO3]+ 
 
m/z 
310  
18 
amu 
Amphetamine 
   
 
[M+H]+ = 136 
 
m/z 
119       
17 
amu 
 
m/z 
91 CH2=CH2 
28 
amu 
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7.2 Study on wipe samples 
7.2.1 Comparison of extraction solvents 
Dichloromethane and acetone were tested for their efficiency to extract fentanyl, 
naloxone and amphetamine from different wipe materials. The efficiency was assessed 
by recovery of the analytes.  The recovery was determined by comparing the peak area 
of the analyte in the standard sample extract to the peak area in the blank sample 
extract spiked with the analyte in the end of the sample preparation. The recoveries 
were calculated using the following equation: 
ܴ݁ܿ݋ݒ݁ݎݕ(%) = ூ௡௧௘௚௥௔௧௘ௗ௣௘௔௞௔௥௘௔௢௙௧௛௘௔௡௔௟௬௧௘௜௡௧௛௘௦௧௔௡ௗ௔௥ௗ௦௔௠௣௟௘௘௫௧௥௔௖௧
ூ௡௧௘௚௥௔௧௘ௗ௣௘௔௞௔௥௘௔௢௙௧௛௘௔௡௔௟௬௧௘௜௡௧௛௘௣௢௦௧–௦௣௜௞௘ௗ௠௔௧௥௜௫௕௟௔௡௞௘௫௧௥௔௖௧  ή 100%  
Table 13 shows mean recoveries and standard deviations (SD) of the analytes from 
wipe samples analyzed by both GC–MS and LC–MS/MS. Calculated recoveries for 
each sample are given in Appendix 3. 
Table 13. Mean recoveries and standard deviations of amphetamine, fentanyl and naloxone from wipe 
samples.  The highest recovery for each analyte is bolded.  
Recoveries, Mean ± SD (%) (n = 6) 
Dichloromethane & water Acetone & water 
DCM fraction Water fraction Acetone fraction Water fraction 
LC–MS2 / GC–MS LC-MS2 / GC–MS LC–MS2 / GC–MS LC–MS2 / GC–MS 
Amphetamine 
Cotton swab 45.6±4.6 / 34.1±4.3 39.4±4.5 / 9.2± 4.0 71.0±2.4 / 33.5±14.8 21.9 ±3.2 / 12.6 ±2.2 
Filter paper 1.2±0.6 / - 65.7±5.2 / 27.8 ± 9.3 57.0±2.7 / 54.0±31.4 31.8 ±3.0 / 7.1 ± 2.5 
Cotton wipe 3.5±1.3 / - 60.9±4.8 / 52.4 ± 12.6 63.4±4.3 / 68.1±30.1 22.8 ±4.4 / - 
Fentanyl 
Cotton swab 77.9±9.6 / 68.6±7.4 7.6±0.7 / 1.9 ± 0.3 80.5 ± 3.7 / 69.3±4.8 5.4 ± 0.8 / 2.2 ± 0.4 
Filter paper 6.7±2.8 / 16.9±3.7 25.7±5.7 / 10.4 ± 1.3 76.2±14.6 / 69.5±7.0 6.3 ± 2.1 / 3.2 ± 0.9 
Cotton wipe 31.4±7.9 / 28.6±2.4 34.3±5.0 / 28.2 ± 9.8 76.7± 2.9 / 83.8±9.0 9.3 ± 2.3 / 5.8 ± 0.9 
Naloxone 
Cotton swab 76.0±3.6 / 66.2±12.0 9.3±1.0 / 2.9 ± 0.2 80.2±1.8 / 70.8±3.4 7.2±0.9 / 3.8±0.6 
Filter paper 18.2±3.2 / 10.2±2.0 45.0±4.7 / 14.9 ± 2.4 86.5±2.4 / 136.8±37.5 8.2±1.4 / - 
Cotton wipe 16.0±1.9 / 16.9±1.4 46.5±5.6 / 49.8 ± 11.9 72.6±4.2 / 85.4±7.3 11.9±2.2 / 8.1±1.6 
Acetone provided significantly higher recoveries for all the analytes compared to 
dichloromethane. In the acetone extracts, the recoveries for fentanyl and naloxone 
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were constantly over 70 % and for amphetamine over 50 %. Dichloromethane 
extracted the analytes poorly from filter paper and cotton wipe but relatively high 
recoveries were achieved from cotton swab. In some cases major difference in 
recovery results can be observed between GC–MS and LC–MS/MS analyses from the 
same extract. Generally, the recoveries analyzed by GC–MS were lower and the SDs 
higher. This may be due to lower sensitivity of GC–MS and the noisy background of the 
chromatogram caused by the silylation reagent. Incomplete silylation of the analytes 
may also have occurred. In some samples the concentrations were too small to be 
analyzed by GC–MS. 
Both organic solvents dissolved the wipes made of cotton: cotton wipes and cotton 
swaps. White solid particles from the wipe matrix appeared in the sample after 
reconstitution of organic extract evaporation residue to water for LC–MS/MS analysis.  
These particles didn’t exist in the filter paper extract. There may have been some loss 
of amphetamine during the evaporation step due to high volatility of the compound, 
although recovery of over 70 % was achieved for amphetamine at highest. However, 
the evaporation to dryness should be avoided if possible. 
7.2.2 Screening 
The ROPs that describe the methods for screening and identifying CWC-related 
chemicals were tested for the candidate chemicals. For the study, a cotton wipe 
containing fentanyl, amphetamine and naloxone (10 µg each) was extracted with 
acetone. Acetone was selected as the extraction solvent due to its high extraction 
efficiency (Table 13). The cotton wipe used in this experiment is the same that the 
OPCW uses in on-site sampling. Two aliquots of acetone extract were prepared, one 
for LC–MS/MS analysis and one for GC–MS analysis. The aliquot prepared for GC–MS 
analysis was silylated with BSTFA. Sample preparation was conducted as described 
earlier (see paragraph 6.1.). 
 GC–MS screening 7.2.2.1
GC–EI-MS analysis produces two kinds of analytical data that can be used in 
screening and identification of the chemical: the mass spectrum and the retention time. 
The identification is performed by comparing the experimental mass spectrum and 
retention time of an unknown chemical to the library mass spectra and retention times 
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of known chemicals. The retention time is usually converted into retention index (RI). 
The RI is calculated by comparing retention time of the analyte of interest to retention 
times of a group of standards. These standards are usually straight chain hydrocarbons 
of different lengths. The RI for each standard is determined by their carbon number 
(the carbon number is multiplied by 100, for example, giving RI of 800 for octane and 
1200 for dodecane). The experimental retention time is compared to the retention times 
of adjacent standards and converted into RI by interpolation. [41] 
The degree that describes how closely the experimental unknown spectrum matches 
the library spectrum is expressed as match factor (MF), reversed match factor (RMF) 
and net match factor (NMF). These match factors give a value ranging from 0 to 1000 
(or from 0 to 100, depending on the numerical scale).  The MF calculation is based on 
similarity of the m/z values and intensities of the peaks in both the unknown spectrum 
and the library spectrum. The difference between RMF and MF is that RMF do not take 
account the extra peaks that are found in the search spectrum but do not exist in the 
library spectrum. This is useful when analyzing compounds in complex matrices, 
although RMF is more likely to give false positive identification. NMF is determined by 
combining both MF and NMF as follows:  
ܰ݁ݐܯܽݐ݄ܿܨܽܿݐ݋ݎ(ܰܯܨ) = 0.75ܯܨ + 0.25ܴܯܨ. [41] 
AMDIS (the Automated Mass Spectral Deconvolution and Identification System) 
software was employed in screening and identification of the candidate chemicals from 
the GC–EI–MS data. The software is able to calculate RIs and to process the GC–MS 
data by extracting spectra for individual components and performing automated 
spectral cleaning. AMDIS searches and identifies target chemicals by comparing the 
found mass spectra to library spectra. The reference mass spectra were recorded and 
the spectral library was built for these candidate chemicals before the screening 
experiment. [42]  
The silylated wipe extract was analyzed with GC–MS on full scan mode (Figure 22). 
The produced data was then analyzed using AMDIS software. The software performed 
spectral cleaning, gave NMF for the found mass spectra and calculated the RIs. Each 
analyte of interest was found by AMDIS. The mass spectra extracted by AMDIS were 
also searched against NIST database which includes a large variety of mass spectra 
produced by different laboratories. Figures 23, 24 and 25 show extracted ion 
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chromatograms and mass spectra of the found compounds. Table 14 lists the 
determined RIs, match factors and total S/N (signal-to-noise) of the extracted ions. 
 
Figure 22. GC–EI–MS TIC of the silylated cotton wipe extract 
 
Figure 23. GC–EI–MS TIC of the silylated cotton wipe extract analyzed by AMDIS showing the presence 
of amphetamine-TMS. Top: TIC with extracted ions m/z 192, 116 and 91, middle: scanned mass spectrum 
at 12.682 min, bottom: extracted mass spectrum at 12.682 min after automatic cleanup by AMDIS. 
Amphetamine-TMS 
Naloxone-3TMS 
Fentanyl 
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Figure 24. GC–EI–MS TIC of the silylated cotton wipe extract analyzed by AMDIS showing the presence 
of fentanyl. Top: TIC with extracted ions m/z 189, 146 and 245, middle: scanned mass spectrum at 28.549 
min, bottom: extracted spectrum at 28.549 min after automatic cleanup by AMDIS. 
 
Figure 25. GC–EI–MS TIC of the silylated cotton wipe extract analyzed by AMDIS showing the presence 
of naloxone-3TMS. Top: TIC with extracted ions m/z 543, 528 and 438, middle: scanned mass spectrum at 
27.748 min, bottom: extracted spectrum at 27.747 min after automatic cleanup by AMDIS. 
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Table 14. RTs, RIs, match factors and S/N of the target analytes in the silylated wipe extract. 
Chemical RT (min) RI NMF (AMDIS) 
MF 
(NIST) 
RMF 
(NIST) 
NMF 
(NIST) 
Total S/N of 
extracted ions 
Fentanyl 28.55 2770 95 927 969 938 125 
Amphetamine-TMS 12.68 1303 93 841 936 865 236 
Naloxone-3TMS 27.75 2682 86 - - - 91 
 
The NMFs computed by AMDIS were high, over 90 for fentanyl and amphetamine-TMS 
and 86 for naloxone-3TMS (maximum 100). The search against NIST database gave 
NMF of 865 and 938 for amphetamine-TMS and fentanyl, respectively (maximum 999). 
No reference spectrum for naloxone-3TMS was found in the NIST database. In OPCW 
Proficiency Test the identification criterion is defined as minimum value of 80 or 800 for 
match factors [41]. Because of the late elution of naloxone-3TMS and fentanyl, the 
retention times were converted to RI by extrapolation. The GC–MS was found to be 
valid technique for screening and identification of the chemicals in question at parts-
per-million (ppm, µg/g) concentration levels. 
 LC–MS/MS screening 7.2.2.2
The first step in LC–MS/MS screening was to analyze the wipe sample extract on LC-
MS  full  scan  mode.  The  [M+H]+ ions of the analytes were then extracted from TIC 
according to their m/z. TIC is shown in Figure 26 and the extracted precursor ion 
chromatograms are seen in Figure 27. The extracted precursor ions distinguished 
clearly from the background offering S/N of 754, 573 and 1882 for fentanyl, naloxone 
and amphetamine, respectively. Also, the precursor ion peaks can be visually detected 
in the TIC. 
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Figure 26. LC–ESI–MS TIC of the wipe extract. 
 
Figure 27. Precursor ions of naloxone (m/z 328), amphetamine (m/z 136) and fentanyl (m/z 337) extracted 
from the LC–ESI–MS TIC. 
After the full scan, targeted screening using MRM was applied for the candidate 
chemicals. This screening is based on searching chemicals with known molecular 
weights, retention times and product ions. The MRM method (Table 9) was developed 
by selecting the product ions to be monitored and optimizing cone voltages for 
precursor ions and collision energies for selected product ions. The ions to be 
monitored were selected according to the product ion spectra of the analytes (see 
Figures 18, 19, 20 and 21). In total seven transitions were monitored. The transitions 
monitored offered excellent S/N of 20 000 or higher (Figure 28).  
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Figure 28. LC–ESI–MS/MS MRM chromatograms of the wipe extract. The transitions monitored were 
(from top to bottom) m/z 337 ĺ 216, m/z 337 ĺ 188 and m/z 337 ĺ 105 for fentanyl, m/z 328 ĺ 310 and 
m/z 328 ĺ 212 for naloxone and m/z 136 ĺ 119 and m/z 136 ĺ 91 for amphetamine. 
The LC–MS/MS was discovered to be valid technique for screening and identification 
of the chemicals in question at parts per million concentration levels. Compared to GC–
MS, the LC–MS/MS was found to be more appropriate technique for analysis of these 
candidate chemicals. Significantly better sensitivity was achieved and the analytes did 
not require derivatization prior to analysis by LC–MS/MS. In addition, the LC–MS/MS 
analysis saved time compared to GC–MS analysis in terms of shorter run times and 
simpler sample preparation.  
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7.3 Analysis of fentanyl in urine 
7.3.1 Linearity 
Linearity was assessed by correlation coefficient (R2) and visual inspection of residual 
plots of the measured calibration curves (n = 9). Figure 29 represents a typical 
calibration curve measured.  Good linearity was achieved for fentanyl in the 
concentration range of 0.5–50 ng/ml. Each calibration curve showed correlation 
coefficient of over 0.9995 and as can be seen in residual plot (Figure 30) the residuals 
are dispersed randomly on both sides of x-axis indicating that the calibration points are 
associated linearly. All the calibration curves and residual plots are given in Appendix 
4. 
 
Figure 29. Typical calibration curve for fentanyl. 
 
Figure 30. Typical residual plot of a fentanyl calibration curve. 
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7.3.2 LOD and LOQ 
Limit of detection (LOD) describes the lowest concentration of analyte at which the 
detection and identification is feasible and the analyte can be reliably distinguished 
from the background noise [43, p.10]. LOD can be calculated from the calibration curve 
(y = mx + n) using equation 
ܮܱܦ = ଷ.ଷήௌ೙
௠
,  
where 
Sn = standard deviation of y-intercepts, 
m = slope [44, p. 11]. 
Limit of quantification (LOQ) is the lowest concentration of analyte that can be 
quantitated with acceptable precision and accuracy [45]. LOD can be calculated from 
the calibration curve (y = mx + n) using equation 
ܮܱܳ = ଵ଴ήௌ೙
௠
, 
where 
Sn = standard deviation of y-intercepts, 
m = slope [44, p. 12].  
LOD and LOQ were calculated for each calibration curve (results are given in Appendix 
5) and method’s LOD and LOQ for fentanyl were expressed as the mean values. LOD 
and LOQ were determined to be 0.4 ng/ml and 1.3 ng /ml, respectively. The calculated 
limits were relatively high and, for instance, the LOQ was higher than the two lowest 
calibration levels. These high limits could be explained by the wide concentration range 
of the calibration curve. Although the linearity was evaluated to be good at range of 
0.5–50 ng/ml fentanyl in urine, the wide concentration range causes relatively large 
deviation on the measured y-intercept values which can be observed as high LOD and 
LOQ. This could be avoided by preparing separate calibration curves for low and high 
concentrations. 
However, as can be seen in the chromatogram of a urine standard at 0.5 ng/ml (Figure 
31), the peaks for transitions m/z 337 ĺ 188 and m/z 337 ĺ 105 are distinguished 
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clearly from the background. The peaks offered mean S/N of 280 for m/z 188 and 60 
for m/z 105. The minimum S/N criteria for LOD and LOQ are typically 3 and 10, 
respectively [44, pp. 11–12]. In addition, the accuracy and precision criteria set for the 
LOQ were satisfied (see paragraph 7.3.5). Hence, the method’s LOD and LOQ for 
fentanyl were determined to be 0.5 ng/ml. It is probable that significantly lower LOD 
and LOQ could be achieved for fentanyl by using lower concentration level calibration 
curve. 
 
Figure 31. LC–ESI–MS/MS MRM chromatograms of a urine standard at 0.5 ng/ml. The transitions 
monitored were (from top to bottom) m/z 342 ĺ 188, m/z 342 ĺ 105 for fentanyl-d5  and m/z 337 ĺ 188, 
m/z 337 ĺ 105 for fentanyl. 
7.3.3 Selectivity 
Selectivity describes the method’s ability to differentiate the analyte from the other 
interfering components in the sample matrix. Selectivity of the method was evaluated 
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by blank samples (no fentanyl or IS spiked) which were analyzed among the validation 
batches. The MRM chromatograms (Figure 32) show no interferences on observed 
transitions in urine blank. 
 
 
Figure 32. LC–MS/MS MRM chromatograms of a urine blank extract. The arrows point out the retention 
time of fentanyl. 
7.3.4 Recovery 
Recovery can be defined as the percentage of analyte in the sample that reaches the 
end of the sample preparation procedure [43, p.12]. The recovery of the analyte can be 
determined by comparing the measured concentration of spiked sample to the true 
reference concentration. Because IS was used in the experiments, the recovery 
standards were prepared by spiking IS in the end of the sample preparation. These 
standards were quantitated against normally prepared calibration curve. Recovery was 
determined at two concentration levels, 1 ng/ml and 25 ng/ml, and was calculated 
using the following equation:  
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ܴ݁ܿ݋ݒ݁ݎݕ(%) =  ௖ೝ
௖ೞ
ή 100%, 
where 
cr = observed concentration of fentanyl in recovery standard and  
cs = true reference concentration of fentanyl in recovery standard. 
 
Calculated mean recoveries and SDs of three replicate recovery samples at 
concentrations of 1 and 25 ng/ml were 83.8 ± 4.5 % and 90.1 ± 3.8 % respectively. The 
recoveries were relatively high which indicates that no major loss of fentanyl occurred 
during the SPE. The measured recoveries are given in Appendix 5. 
7.3.5 Accuracy and precision 
Accuracy can be defined as closeness of an observed result to a true reference value 
of a sample. Accuracy is sometimes referred as trueness. It expresses the systematic 
error that occurs in measurements and can be reported as bias. The relative bias is 
calculated using the equation 
ܾ(%) = ௫ҧି௫ೝ೐೑
௫ೝ೐೑
ή 100%, 
where 
b(%) = relative bias in per cent 
xࡄ  = mean of the observed value 
xref = true reference value. [46, p.31] 
Precision describes the closeness of results to one another. It usually expresses the 
random error that occurs in the method and can be reported as variance, standard 
deviation or relative standard deviation. Precision can be divided into different 
components: repeatability, reproducibility and intermediate precision. To calculate 
those components, variance results from one-way analysis of variance (ANOVA) by 
Microsoft Excel were used (Appendix 6). Repeatability describes method’s ability to 
give results as close as possible to the same value when measurements are made 
during a short timescale and the conditions are unchanged. Repeatability standard 
deviation can be determined using equation 
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ݏ௪ = ඥܯܵ௪,  
where 
sw = repeatability standard deviation 
MSw = mean square within group (obtained from ANOVA). [46, 35] 
Reproducibility describes variability of results between laboratories and is considered 
to give the maximum variation in results. It can be determined only in interlaboratory 
experiments. Intermediate precision (within-laboratory reproducibility) combines within- 
and between-run variations and describes the variation in results when measurements 
are performed in a single laboratory but the conditions are changed. In this method 
validation day-to-day variability was evaluated. The between-run standard deviation 
was calculated using equation 
ݏ௕ = ටெௌ್ିெௌೢ௡ ,  
where 
MSb = mean square between groups (obtained from ANOVA), 
MSw = mean square within group (obtained from ANOVA) and  
n = number of replicate samples in a group [46, p. 35]. 
The intermediate precision was calculated combining the within- and between-run 
variances using equation  
ݏ௧௢௧ = ටݏ௪ଶ + ݏ௕ଶ . 
Precision results were expressed as relative standard deviations using equation 
%ܴܵܦ = ௦ೣ
௫ҧ
ή 100%, 
where 
sx = within-run, between-run or intermediate precision and 
xࡄ  = mean result at observed concentration level. 
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Standard samples used in accuracy and precision calculations were quantitated 
against a calibration curve with three points per calibration level prepared each day 
(Figure 33). For each concentration level, three separate batches (n = 3 each) were 
analyzed and the within- and between-day variations were determined. The accuracy 
and precision results for each concentration level are summarized in Table 15. 
 
Figure 33. Typical calibration curve with triplicate calibration points prepared each day for quantitation of 
the standard samples. 
Table 15. The accuracy and precision results for fentanyl. 
Standard 
level 
(ng/ml) 
Observed 
mean c 
(ng/ml)  
SD 
(ng/ml) RSD (%) 
Bias 
(%) 
Within-day 
variation 
(%) 
Between-
day 
variation 
(%) 
Intermediate 
precision (%) 
0.5 0.57 0.028 4.9 14.3 5.0 1.1 5.2 
1 1.03 0.063 6.1 3.3 6.0 1.4 6.1 
5 5.07 0.11 2.1 1.3 2.0 0.9 2.2 
10 9.88 0.22 2.2 -1.2 2.4 1.2 2.7 
25 24.75 0.67 2.7 -1.0 2.7 0.4 2.7 
50 50.14 1.05 2.1 0.3 2.4 1.3 2.7 
Accuracy, expressed as relative bias, ranged from -1.2 % to 14.3 %. US Food and 
Drug Administration (FDA) has set criteria for method accuracy in bioanalytical method 
validation. According to those criteria the measured mean value should not deviate 
more than 15 % from the true value (except at LOQ the mean should be within 20 % 
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from the actual value). The measured mean values were inside the 15 % tolerance 
window at every concentration level. Overall the method showed good accuracy. The 
highest calculated intermediate precision was 6.1 % at concentration level of 1 ng /ml. 
According to FDA, the determined precision should not exceed 15 % of RSD. Neither 
the calculated RSD nor the intermediate precision exceeded that limit at any 
concentration level. Generally, excellent precision was achieved. [47, p. 5]  
7.3.6 Relative ion abundances 
In order to prevent the risk of false positive identification of fentanyl, the detected 
product ion abundance ratios were determined in standard samples and unknown 
samples and compared. The peak area ratio between qualifier (q) and quantifier ion (Q) 
is calculated by dividing the peak area of the less abundant ion by the peak area of the 
more abundant ion and multiplying with 100 %. World Anti-doping Agency (WADA) has 
set criterion for the maximum permitted difference in relative ion abundances between 
standard and unknown samples. When the peak area ratio between detected ions in 
standard samples is 50 % or higher, the maximum permitted tolerance for relative ion 
abundance in the unknown sample is ±10 % (absolute) [48]. 
Relative ion abundances may vary depending on the concentration of analyte. The ion 
ratio for fentanyl (q/Q) was calculated from the standard samples at level 25 ng/ml. The 
integrated peak areas and the calculated relative ion abundances are given in 
Appendix 5. The mean ion ratio in standard samples was 88.4 % and, consequently, 
the tolerance window was 78.4–98.4 % for an unknown sample.  
7.3.7 Authentic sample 
Seven replicate samples were prepared from the urine of the surgical patient. The 
samples were analyzed within four days during the validation experiments. The 
measured mean concentration (± SD) for fentanyl in urine was 20.9 ± 1.2 ng/ml (Table 
16). Representative MRM chromatograms of the authentic urine sample are shown in 
Figure 34. The relative abundance of fentanyl product ions in each sample was inside 
the determined tolerance window (88.4 ± 10 %) ensuring with appropriate confidence 
that the compound detected is fentanyl. 
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Table 16. RTs, ion ratios, S/N and observed concentration of fentanyl in the surgical patient’s urine 
sample. 
Sample ID 
Integrated peak area 
Ion ratio (%) RT (min) S/N   (m/z 188) 
Observed c 
(ng/ml) m/z 105 m/z 188 
1 16497 14022 85.0 2.42 701 20.2 
2 17314 16210 93.6 2.41 609 22.1 
3 16830 15463 91.9 2.41 622 22.7 
4 15187 14342 94.4 2.40 657 21.6 
5 12556 11531 91.8 2.40 465 20.1 
6 19709 18491 93.8 2.40 795 20.6 
7 16835 15731 93.4 2.40 627 19.3 
    Mean concentration (ng/ml) 20.9 
    SD (ng/ml) 1.2 
 
Figure 34. LC–MS/MS MRM chromatograms of the surgical patient's urine sample. The transitions 
monitored were (from top to bottom) m/z 342 ĺ 188, m/z 342 ĺ 105 for fentanyl-d5  and m/z 337 ĺ 188, 
m/z 337 ĺ 105 for fentanyl. 
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8 Conclusion 
The present thesis describes a study on analytical methods for detecting CNS acting 
chemicals. The study includes a review of existing literature on selected candidate 
chemicals, testing of the ROPs for sample preparation, analysis, screening and 
identification of the substances in wipe samples and a validation of a method for 
determining fentanyl in human urine. Chemicals selected for the study were CNS 
acting drugs: amphetamine, diazepam, naloxone and fentanyl. The availability of the 
reference chemicals was investigated. Diazepam had to be left outside of the ROP 
testing experiments due to delivery problems of the reference chemical. Fentanyl, 
amphetamine and diazepam are drugs with narcotic properties, and they are covered 
under Finnish narcotic legislation. Therefore, the purchase of the reference chemicals 
required applying licenses from Fimea for importing and handling the narcotics in 
question. This was somewhat time consuming process.  
The experimental can be divided into two sections. In the first part, a study on detecting 
amphetamine, naloxone and fentanyl in wipe samples was carried out. Different 
organic solvents, dichloromethane and acetone, and water were tested for their 
efficiency to extract selected candidate chemicals from spiked wipe samples. The wipe 
samples were extracted successively with organic and aqueous solvents and the 
extraction efficiency was assessed by recovery of the analytes. Three different wipe 
materials were used in this ROP testing experiment. Acetone was found to give 
significantly higher recoveries for all the candidate chemicals compared to 
dichloromethane. The water extraction performed after dichloromethane extraction 
provided relatively high recoveries for the analytes. According to these results, acetone 
is highly recommended solvent to be used for extraction of the chemicals in question 
from wipe samples. 
The candidate chemicals were screened and identified from acetone extract of a spiked 
cotton wipe sample. The extract was screened using both LC–MS/MS and GC–MS 
techniques and methods described in the ROPs. The GC–MS analysis required 
derivatization of amphetamine and naloxone with BSTFA. The GC–MS screening 
based on analysis of the produced full scan data by AMDIS software. In the LC–
MS/MS screening, the precursor ions were extracted from the LC–MS full scan TIC. 
After that, the transitions characteristic to the target chemicals were detected using 
MRM. Both GC–MS and LC–MS/MS techniques and the tested ROPs were discovered 
51 
  
to be valid for screening and identification of the candidate chemicals at parts-per-
million (ppm, µg/g) concentration levels. From these two analysis techniques, the LC–
MS/MS was found to be more appropriate technique for analysis of the chemicals in 
question. The recorded EI mass spectra of the analytes will be submitted for evaluation 
and inclusion in the OCAD in the future. 
The second section of experimental part included a validation of a quantitative analysis 
of fentanyl in human urine by LC–ESI–MS/MS. The assay was based on extracting 
fentanyl from urine by SPE. The validation parameters studied were linearity, 
selectivity, LOD, LOQ, recovery, accuracy and precision. The method showed good 
linearity in the range of 0.5–50 ng/ml fentanyl in human urine. LOD and LOQ were 
calculated from the calibration curve. According to the calculations, LOQ was estimated 
to be higher than the lowest concentration levels used in the validation experiments. It 
is possible that these high limits result from the excessively wide concentration range 
of the calibration curve. Hence, it is recommended that calibration curves should be 
prepared for low and high concentrations separately. However, the S/N, accuracy and 
precision at the lowest observed concentration level satisfied the criteria set for LOQ 
and therefore LOD and LOQ for fentanyl in urine were determined to be 0.5 ng/ml. It is 
very likely that by using lower concentration level calibration curve, significantly lower 
LOD and LOQ would be achieved. 
The SPE procedure yielded recoveries of over 80 %. The high recoveries indicated that 
the extraction procedure did not a cause significant loss of fentanyl. Accuracy (bias) 
was determined to be lower than 5 % at every concentration level except for the lowest 
level (14.3%). The intermediate precision was maximum 6.1 %. The method accuracy 
and precision were inside the acceptance criteria of 15 % set in the guidelines for 
bioanalytical method validation by FDA. Overall the method showed excellent accuracy 
and precision. 
In addition to the validation, an authentic urine sample from a surgical patient who was 
given fentanyl intravenously prior to the operation was analyzed. In total, seven 
replicate samples were prepared and analyzed. The mean concentration of fentanyl in 
urine was observed to be 20.9 ng/ml. The relative ion abundance in each measured 
replicate sample was inside the determined tolerance window assuring that the 
compound detected is fentanyl. 
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Appendix 1. Hard copy of the accompanying information for the mass 
spectra submitted to the OCAD 
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Appendix 2. Total ion chromatogram of a silylated naloxone standard 
 
 
The 100 µg/ml naloxone standard was silylated with BSTFA. Peak A is 
pertrimethylsilated naloxone-3TMS. Two silylation products (naloxone-TMS and 
naloxone-2TMS) elute with the same retention time in peak B. Peak C represents the 
fourth silylation product of naloxone with two TMS groups attached.
A 
B 
C 
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Appendix 3. Recoveries from the wipe samples 
 
 
Wipe: Whatman filter paper  Solvents: Acetone & water   Analysis: LC–MS/MS   
Recovery (%), acetone fraction 
Sample ID Amphetamine Naloxone Fentanyl 
150721TK01e 58.7 90,7 90,8 
150721TK02e 61.4 87,8 54,6 
150721TK03e 54,1 84,9 62,8 
150721TK04e 57,1 84,7 86.5 
150721TK05e 54.6 86.5 76.4 
150721TK06e 56.2 84.3 86.1 
Mean 57.0 86.5 76.2 
SD 2.7 2.4 14.6 
RSD 4.8 2.8 19.1 
Recovery (%). water fraction 
Sample ID Amphetamine Naloxone Fentanyl 
150721TK01c 27.1 6.8 9.1 
150721TK02c 34.3 8.0 6.0 
150721TK03c 29.4 6.3 4.8 
150721TK04c 34.0 9.6 4.9 
150721TK05c 33.9 9.1 7.3 
150721TK06c 32.2 9.2 5.8 
Mean 31.8 8.2 6.3 
SD 3.0 1.4 1.6 
RSD 9.3 16.8 25.9 
 
Wipe: Whatman filter paper 
  Solvents: Acetone & water 
  Analysis: GC–MS 
  Recovery (%). acetone fraction 
Sample ID Amphetamine Naloxone Fentanyl 
150721TK01b 54.3 157.3 58.4 
150721TK02b 112.8 159.1 76.4 
150721TK03b 35.7 189.9 77.0 
150721TK04b 45.0 113.4 65.3 
150721TK05b 21.4 109.0 69.2 
150721TK06b 54.6 92.4 70.5 
Mean 54.0 136.8 69.5 
SD 31.4 37.5 7.0 
RSD 58.2 27.4 10.1 
Recovery (%). water fraction 
Sample ID Amphetamine Naloxone Fentanyl 
150721TK01d 5.1 - 3.0 
150721TK02d 6.9 - 2.8 
150721TK03d 4.8 - 2.4 
150721TK04d 10.9 - 3.3 
150721TK05d 0.0 - 4.9 
150721TK06d 7.6 - 2.5 
Mean 7.1 - 3.2 
SD 2.5 - 0.9 
RSD 34.7 - 28.3 
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Wipe: Whatman filter paper 
 Solvents: Dichloromethane & water 
  Analysis: LC–MS/MS 
  Recovery (%), dichloromethane fraction 
Sample ID Amphetamine Naloxone Fentanyl 
150727TK01a 1.3 20.5 10.0 
150727TK02a 0.9 20.3 8.2 
150727TK03a 1.5 15.2 5.1 
150727TK04a 0.8 14.9 3.9 
150727TK05a 0.7 16.0 3.8 
150727TK06a 2.1 22.3 9.4 
Mean 1.2 18.2 6.7 
SD 0.6 3.2 2.8 
RSD 45.4 17.8 41.9 
Recovery (%), water fraction 
Sample ID Amphetamine Naloxone Fentanyl 
150727TK01c 65.3 45.8 30.6 
150727TK02c 67.2 43.6 22.4 
150727TK03c 67.5 46.6 24.0 
150727TK04c 71.9 50.3 33.5 
150727TK05c 56.1 36.6 17.7 
150727TK06c 65.9 47.3 26.2 
Mean 65.7 45.0 25.7 
SD 5.2 4.7 5.7 
RSD 8.0 10.4 22.1 
 
Wipe: Whatman filter paper 
  Solvents: Dichloromethane & water 
  Analysis: GC–MS 
  Recovery (%), dichloromethane fraction 
Sample ID Amphetamine Naloxone Fentanyl 
150727TK01b - 11.2 15.0 
150727TK02b - 12.9 22.7 
150727TK03b - 11.1 20.2 
150727TK04b - 8.8 15.9 
150727TK05b - 7.1 12.8 
150727TK06b - 10.0 14.9 
Mean - 10.2 16.9 
SD - 2.0 3.7 
RSD - 19.7 22.2 
Recovery (%), water fraction 
Sample ID Amphetamine Naloxone Fentanyl 
150727TK01d 21.9 15.5 12.5 
150727TK02d 38.3 12.2 9.2 
150727TK03d 24.5 16.2 10.2 
150727TK04d 39.6 14.8 10.2 
150727TK05d 26.8 12.3 8.9 
150727TK06d 16.0 18.6 11.1 
Mean 27.8 14.9 10.4 
SD 9.3 2.4 1.3 
RSD 33.5 16.4 12.8 
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Wipe: Cotton swab 
  Solvents: Acetone & water 
  Analysis: LC–MS/MS 
  Recovery (%), acetone fraction 
Sample ID Amphetamine Naloxone Fentanyl 
150729TK01a 69.6 78.4 83.1 
150729TK02a 69.8 78.1 75.9 
150729TK03a 72.0 82.3 83.1 
150729TK04a 75.3 81.9 84.2 
150729TK05a 69.0 80.9 80.3 
150729TK06a 70.3 79.4 76.0 
Mean 71.0 80.2 80.5 
SD 2.4 1.8 3.7 
RSD 3.3 2.2 4.6 
Recovery (%), water fraction 
Sample ID Amphetamine Naloxone Fentanyl 
150729TK01c 23.1 6.4 5.1 
150729TK02c 23.3 7.9 6.2 
150729TK03c 25.4 7.2 6.2 
150729TK04c 16.0 5.9 4.1 
150729TK05c 22.1 8.4 5.5 
150729TK06c 21.5 7.2 5.0 
Mean 21.9 7.2 5.4 
SD 3.2 0.9 0.8 
RSD 14.5 13.2 15.1 
 
Wipe: Cotton swap 
  Solvents: Acetone & water 
  Analysis: GC–MS 
  Recovery (%), acetone fraction 
Sample ID Amphetamine Naloxone Fentanyl 
150729TK01b 57.0 72.1 68.0 
150729TK02b 35.0 69.8 76.7 
150729TK03b 28.4 67.7 62.0 
150729TK04b 19.2 74.5 68.9 
150729TK05b 42.7 74.2 71.3 
150729TK06b 18.7 66.4 69.1 
Mean 33.5 70.8 69.3 
SD 14.8 3.4 4.8 
RSD 44.1 4.8 6.9 
Recovery (%), water fraction 
Sample ID Amphetamine Naloxone Fentanyl 
150729TK01d 12.2 2.9 2.3 
150729TK02d 11.1 3.6 3.0 
150729TK03d 12.9 3.8 2.1 
150729TK04d 13.7 4.4 1.9 
150729TK05d 16.2 4.0 1.9 
150729TK06d 9.7 4.3 2.2 
Mean 12.6 3.8 2.2 
SD 2.2 0.6 0.4 
RSD 17.5 14.7 18.5 
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Wipe: Cotton swab 
  Solvents: Dichloromethane & water 
 Analysis: LC–MS/MS 
  Recovery (%), acetone fraction 
Sample ID Amphetamine Naloxone Fentanyl 
150723TK01a 52.5 79.0 67.0 
150723TK02a 48.6 80.8 84.4 
150723TK03a 43.9 72.9 85.6 
150723TK04a 39.1 72.9 88.4 
150723TK05a 45.5 77.5 67.0 
150723TK06a 44.1 72.9 74.9 
Mean 45.6 76.0 77.9 
SD 4.6 3.6 9.6 
RSD 10.0 4.7 12.3 
Recovery (%), water fraction 
Sample ID Amphetamine Naloxone Fentanyl 
150723TK01c 37.2 8.7 7.2 
150723TK02c 43.5 9.3 7.3 
150723TK03c 34.3 8.2 6.7 
150723TK04c 34.9 8.6 7.7 
150723TK05c 42.3 10.8 8.7 
150723TK06c 44.1 10.1 7.9 
Mean 39.4 9.3 7.6 
SD 4.5 1.0 0.7 
RSD 11.3 10.7 9.2 
 
Wipe: Cotton swab 
  Solvents: Dichloromethane & water 
 Analysis: GC–MS 
  Recovery (%), acetone fraction 
Sample ID Amphetamine Naloxone Fentanyl 
150723TK01b 
150723TK02b 
30.7 
35.6 
42.3 
70.5 
59.6 
77.0 
150723TK03b 34.4 73.4 66.6 
150723TK04b 39.8 74.2 73.2 
150723TK05b 27.8 69.7 74.5 
150723TK06b 36.4 66.7 60.6 
Mean 34.1 66.2 68.6 
SD 4.3 12.0 7.4 
RSD 12.6 18.1 10.8 
Recovery (%), water fraction 
Sample ID Amphetamine Naloxone Fentanyl 
150723TK01d 7.9 3.1 2.0 
150723TK02d 7.0 3.1 2.3 
150723TK03d 9.4 2.6 1.6 
150723TK04d 7.7 2.6 2.0 
150723TK05d 6.5 3.0 1.9 
150723TK06d 17.0 2.6 1.4 
Mean 9.2 2.9 1.9 
SD 4.0 0.2 0.3 
RSD 42.7 8.3 17.3 
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Wipe: Cotton wipe 
  Solvents: Acetone & water 
  Analysis: LC–MS/MS 
  Recovery (%), acetone fraction 
Sample ID Amphetamine Naloxone Fentanyl 
150804TK01a 70.6 79.4 78.6 
150804TK02a 65.4 72.6 81.6 
150804TK03a 60.6 68.1 73.7 
150804TK04a 58.5 69.8 75.4 
150804TK05a 61.7 70.1 76.1 
150804TK06a 63.9 75.5 74.9 
Mean 63.4 72.6 76.7 
SD 4.3 4.2 2.9 
RSD 6.7 5.8 3.8 
Recovery (%), water fraction 
Sample ID Amphetamine Naloxone Fentanyl 
150804TK01c 15.4 8.2 5.5 
150804TK02c 20.8 12.2 8.6 
150804TK03c 21.8 11.6 9.2 
150804TK04c 27.2 13.3 11.7 
150804TK05c 26.2 14.6 11.8 
150804TK06c 25.2 11.8 9.3 
Mean 22.8 11.9 9.3 
SD 4.4 2.2 2.3 
RSD 19.2 18.0 24.9 
 
Wipe: Cotton wipe 
  Solvents: Acetone & water 
  Analysis: GC–MS 
  Recovery (%), acetone fraction 
Sample ID Amphetamine Naloxone Fentanyl 
150804TK01b 106.9 82.5 76.9 
150804TK02b 73.71 77.1 76.4 
150804TK03b 32.9 81.9 76.4 
150804TK04b 88.1 82.4 83.6 
150804TK05b 75.1 97.3 96.1 
150804TK06b 31.9 90.9 93.7 
Mean 68.1 85.4 83.8 
SD 30.1 7.3 9.0 
RSD 44.2 8.6 10.8 
Recovery (%), water fraction 
Sample ID Amphetamine Naloxone Fentanyl 
150804TK01d - 8.0 5.6 
150804TK02d - 6.2 4.9 
150804TK03d - 6.8 5.2 
150804TK04d - 10.6 6.8 
150804TK05d - 9.2 7.0 
150804TK06d - 7.5 5.4 
Mean - 8.1 5.8 
SD - 1.6 0.9 
RSD - 19.8 14.8 
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Wipe: Cotton wipe 
  Solvents: Dichloromethane & water 
 Analysis: LC–MS/MS 
  Recovery (%), dichloromethan fraction 
Sample ID Amphetamine Naloxone Fentanyl 
150730TK02a 3.3 15.8 23.2 
150730TK03a 2.8 16.3 35.8 
150730TK04a 2.1 19.4 39.3 
150730TK05a 2.8 15.4 24.1 
150730TK06a 5.7 14.3 25.8 
150730TK07a 4.1 14.5 40.3 
Mean 3.5 16.0 31.4 
SD 1.3 1.9 7.9 
RSD 36.6 11.7 25.2 
Recovery (%), water fraction 
Sample ID Amphetamine Naloxone Fentanyl 
150730TK02c 64.9 41.7 29.2 
150730TK03c 60.5 46.3 34.6 
150730TK04c 56.5 47.7 39.2 
150730TK05c 68.6 56.8 40.4 
150730TK06c 57.9 41.7 28.1 
150730TK07c 57.3 44.5 34.2 
Mean 60.9 46.5 34.3 
SD 4.8 5.6 5.0 
RSD 8.0 12.1 14.6 
 
Wipe: Cotton wipe 
  Solvents: Dichloromethane & water 
 Analysis: GC–MS 
  Recovery (%), dichloromethane fraction 
Sample ID Amphetamine Naloxone Fentanyl 
150730TK02b - 17.3 25.6 
150730TK03b - 19.4 30.5 
150730TK04b - 16.9 29.9 
150730TK05b - 15.5 31.5 
150730TK06b - 15.8 27.2 
150730TK07b - 16.3 26.5 
Mean - 16.9 28.6 
SD - 1.4 2.4 
RSD - 8.5 8.5 
Recovery (%), water fraction 
Sample ID Amphetamine Naloxone Fentanyl 
150730TK02d 51.8 29.7 12.8 
150730TK03d 49.9 42.8 24.1 
150730TK04d 59.3 52.4 33.0 
150730TK05d 40.9 60.4 36.8 
150730TK06d 39.2 52.2 23.8 
150730TK07d 73.1 61.0 38.7 
Mean 52.4 49.8 28.2 
SD 12.6 11.9 9.8 
RSD 24.0 23.8 34.7 
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Appendix 4. Calibration curves and residual plots 
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Appendix 5. Validation results 
  LOD and LOQ 
  
Slope, m y-intercept, n Correlation coefficient (R2) LOD (ng/ml) LOQ (ng/ml) 
Day 1 
Batch 1 0.1035 -0.0130 0.9999 0.408 1.235 
Batch 2 0.0961 0.0096 0.9998 0.439 1.331 
Batch 3 0.0996 -0.0066 0.9999 0.424 1.284 
Day 2 
Batch 1 0.0976 -0.0096 0.9997 0.432 1.310 
Batch 2 0.1001 -0.0100 0.9999 0.422 1.278 
Batch 3 0.0992 -0.0122 0.9997 0.425 1.289 
Day 3 
Batch 1 0.1050 0.0146 0.9995 0.402 1.218 
Batch 2 0.1061 -0.0011 0.9999 0.398 1.206 
Batch 3 0.1079 -0.0284 0.9996 0.391 1.184 
Standard deviation of y-intercepts 0.0128 Average LOD and LOQ 0.416 1.259 
 
Recoveries 
Sample ID c (ng/ml) Area ratio c (ng/ml) Recovery (%) 
150904TK18 1 0.088 0.801 80.1 
150904TK19 1 0.091 0.826 82.6 
150904TK20 1 0.097 0.888 88.8 
150904TK21 25 2.426 23.2 92.7 
150904TK22 25 2.407 23.0 92.0 
150904TK23 25 2.244 21.4 85.7 
   
Average (1 ng/ml) 83.8 
   
SD (1 ng/ml) 4.5 
   
Average (25 ng/ml) 90.1 
   
SD (25 ng/ml) 3.8 
 
 Observed concentration of standard samples (ng/ml) 
 
Standard level (ng/ml) 0.5 1 5 10 25 50 
Day 1 
0.57 0.97 5.02 10.25 25.44 52.03 
0.58 1.09 5.28 9.88 23.68 48.52 
0.56 1.06 5.04 9.63 24.78 50.01 
Day 2 
0.59 1.07 5.11 9.75 24.05 49.63 
0.60 1.09 5.11 10.04 24.82 50.82 
0.58 1.04 5.08 9.97 24.39 50.43 
Day 3 
0.60 1.00 5.06 10.04 25.75 49.12 
0.57 1.07 5.01 9.73 25.28 49.81 
0.50 0.90 4.87 9.58 24.52 50.93 
Mean 0.57 1.03 5.07 9.88 24.75 50.14 
SD 0.03 0.06 0.11 0.22 0.67 1.05 
%RSD 4.93 6.07 2.13 2.23 2.70 2.09 
Systematic error (ng/ml), bias 0.07 0.03 0.07 -0.12 -0.25 0.14 
Systematic error (%), bias% 14.33 3.31 1.33 -1.24 -1.01 0.29 
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Relative ion abundaces in standard samples at 25 ng/ml 
Sample ID c (ng/ml) Area (m/z 188) Area (m/z 105) Relative Ion abundance (%) 
150825TK06 25 30027 35101 85.5 
150825TK14 25 29187 32015 91.2 
150825TK22 25 32623 37302 87.5 
150928TK11 25 41349 50678 81.6 
150928TK18 25 46489 56452 82.4 
150928TK25 25 42431 51606 82.2 
150903TK12 25 38096 40645 93.7 
150903TK19 25 34315 37902 90.5 
150903TK26 25 37639 39864 94.4 
150904TK09 25 38466 41694 92.3 
150904TK16 25 36738 40362 91.0 
  
Mean relative ion abundance (%) 88.4 
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Appendix 6. Analysis of variance 
c (fentanyl) = 0.5 ng/ml 
Anova: Single Factor 
SUMMARY 
Groups Count Sum Average Variance 
day 1 3 1.7045725 0.5681908 0.0001506 
day 2 3 1.7651746 0.5883915 4.353E-05 
day 3 3 1.675172 0.5583907 0.0022872 
ANOVA 
Source of Variation SS df MS F P-value F crit 
Between Groups 0.001404164 2 0.0007021 0.848831 0.4735624 5.1432528 
Within Groups 0.004962697 6 0.0008271 
Total 0.006366861 8         
  
sw 0.0288 sw (%) 5.03 
sb 0.0065 sb (%) 1.13 
stot 0.0295 stot (%) 5.16 
 
c(fentanyl) = 1 ng/ml 
Anova: Single Factor 
SUMMARY 
Groups Count Sum Average Variance 
day 1 3 3.1251907 1.0417302 0.0041671 
day 2 3 3.198914 1.0663047 0.0005049 
day 3 3 2.9740057 0.9913352 0.0066641 
ANOVA 
Source of Variation SS df MS F P-value F crit 
Between Groups 0.008763974 2 0.004382 1.1596612 0.375137 5.1432528 
Within Groups 0.022672071 6 0.0037787 
Total 0.031436045 8         
  
sw 0.061 sw (%) 5.95 
sb 0.014 sb (%) 1.37 
stot 0.063 stot (%) 6.11 
 
c (fentanyl) = 5 ng/ml 
Anova: Single Factor 
SUMMARY 
Groups Count Sum Average Variance 
day 1 3 15.349555 5.1165183 0.020373 
day 2 3 15.303055 5.1010184 0.000305 
day 3 3 14.945317 4.9817722 0.0097974 
ANOVA 
Source of Variation SS df MS F P-value F crit 
Between Groups 0.032616391 2 0.0163082 1.6053858 0.2764176 5.1432528 
Within Groups 0.060950566 6 0.0101584 
Total 0.093566957 8         
  
sw 0.101 sw (%) 1.99 
sb 0.045 sb (%) 0.89 
stot 0.110 stot (%) 2.18 
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c (fentanyl) = 10 ng/ml 
Anova: Single Factor 
SUMMARY 
Groups Count Sum Average Variance 
day 1 3 29.760962 9.9203207 0.0957591 
day 2 3 29.76671 9.9222366 0.0228458 
day 3 3 29.354794 9.7849314 0.0559453 
ANOVA 
Source of Variation SS df MS F P-value F crit 
Between Groups 0.037186651 2 0.0185933 0.319564 0.7381092 5.1432528 
Within Groups 0.349100523 6 0.0581834 
Total 0.386287174 8         
  
sw 0.241 sw (%) 2.44 
sb 0.115 sb (%) 1.16 
stot 0.267 stot (%) 2.71 
 
c (fentanyl) = 25 ng/ml 
Anova: Single Factor 
SUMMARY 
Groups Count Sum Average Variance 
day 1 3 73.903374 24.634458 0.7903887 
day 2 3 73.269249 24.423083 0.147505 
day 3 3 75.554831 25.184944 0.385823 
ANOVA 
Source of Variation SS df MS F P-value F crit 
Between Groups 0.928145828 2 0.4640729 1.0517498 0.4059158 5.1432528 
Within Groups 2.647433459 6 0.4412389 
Total 3.575579287 8         
  
sw 0.664 sw (%) 2.68 
sb 0.087 sb (%) 0.35 
stot 0.670 stot (%) 2.71 
 
c (fentanyl) = 50 ng/ml 
Anova: Single Factor 
SUMMARY 
Groups Count Sum Average Variance 
day 1 3 150.55662 50.185539 3.1136881 
day 2 3 150.8751 50.291699 0.3686536 
day 3 3 149.85586 49.951954 0.8345555 
ANOVA 
Source of Variation SS df MS F P-value F crit 
Between Groups 0.181258742 2 0.0906294 0.0629823 0.9395725 5.1432528 
Within Groups 8.633794443 6 1.4389657 
Total 8.815053185 8         
  
sw 1.200 sw (%) 2.39 
sb 0.670 sb (%) 1.34 
stot 1.374 stot (%) 2.74 
 
